. 2017 Feb; 168(4):707-723.
doi: 10.1016/j.cell.2017.01.017.

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma 1 Siwen Hu-Lieskovan 2 Jennifer A Wargo 3 Antoni Ribas 4 
  • PMID: 28187290
  •     181 References
  •     1386 citations


Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion. As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.

Keywords: T cells; immunotherapy; resistance mechanisms.

Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
Hyun-Jung Kim, Suk-Chul Bae.
Am J Transl Res, 2011 Mar 19; 3(2). PMID: 21416059    Free PMC article.
Highly Cited.
Augmenting antitumor immune responses with epigenetic modifying agents.
Erika Héninger, Timothy E G Krueger, Joshua M Lang.
Front Immunol, 2015 Feb 24; 6. PMID: 25699047    Free PMC article.
Highly Cited. Review.
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
Padmanee Sharma, James P Allison.
Cell, 2015 Apr 11; 161(2). PMID: 25860605    Free PMC article.
Highly Cited. Review.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Cell interactions in the induction of tolerance: the role of thymic lymphocytes.
R K Gershon, K Kondo.
Immunology, 1970 May 01; 18(5). PMID: 4911896    Free PMC article.
Highly Cited.
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Marie Vétizou, Jonathan M Pitt, +35 authors, Laurence Zitvogel.
Science, 2015 Nov 07; 350(6264). PMID: 26541610    Free PMC article.
Highly Cited.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
The journey from discoveries in fundamental immunology to cancer immunotherapy.
Jacques F A P Miller, Michel Sadelain.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858803
Highly Cited. Review.
A critical function for type I interferons in cancer immunoediting.
Gavin P Dunn, Allen T Bruce, +8 authors, Robert D Schreiber.
Nat Immunol, 2005 Jun 14; 6(7). PMID: 15951814
Highly Cited.
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Michael R Green, Stefano Monti, +9 authors, Margaret A Shipp.
Blood, 2010 Jul 16; 116(17). PMID: 20628145    Free PMC article.
Highly Cited.
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.
Edward Y Woo, Heidi Yeh, +5 authors, Carl H June.
J Immunol, 2002 Apr 24; 168(9). PMID: 11970966
Highly Cited.
Cancer immunoediting: from immunosurveillance to tumor escape.
Gavin P Dunn, Allen T Bruce, +2 authors, Robert D Schreiber.
Nat Immunol, 2002 Oct 31; 3(11). PMID: 12407406
Highly Cited. Review.
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y Ishida, Y Agata, K Shibahara, T Honjo.
EMBO J, 1992 Nov 01; 11(11). PMID: 1396582    Free PMC article.
Highly Cited.
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
Subhra K Biswas, Alberto Mantovani.
Nat Immunol, 2010 Sep 22; 11(10). PMID: 20856220
Highly Cited. Review.
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.
Thinle Chodon, Begoña Comin-Anduix, +31 authors, Antoni Ribas.
Clin Cancer Res, 2014 Mar 19; 20(9). PMID: 24634374    Free PMC article.
Highly Cited.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo.
Anette Sundstedt, Emma J O'Neill, Kirsty S Nicolson, David C Wraith.
J Immunol, 2003 Jan 23; 170(3). PMID: 12538682
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
Soranobu Ninomiya, Neeharika Narala, +7 authors, Carlos A Ramos.
Blood, 2015 May 06; 125(25). PMID: 25940712    Free PMC article.
Highly Cited.
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Weiping Zou, Jedd D Wolchok, Lieping Chen.
Sci Transl Med, 2016 Mar 05; 8(328). PMID: 26936508    Free PMC article.
Highly Cited. Review.
Reactivating the expression of methylation silenced genes in human cancer.
Adam R Karpf, David A Jones.
Oncogene, 2002 Aug 03; 21(35). PMID: 12154410
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
Andrea Boni, Alexandria P Cogdill, +9 authors, Jennifer A Wargo.
Cancer Res, 2010 Jun 17; 70(13). PMID: 20551059
Highly Cited.
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Richard A Morgan, Mark E Dudley, +13 authors, Steven A Rosenberg.
Science, 2006 Sep 02; 314(5796). PMID: 16946036    Free PMC article.
Highly Cited.
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
F M Marincola, E M Jaffee, D J Hicklin, S Ferrone.
Adv Immunol, 1999 Dec 22; 74. PMID: 10605607
Highly Cited. Review.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
Eric Tran, Paul F Robbins, +9 authors, Steven A Rosenberg.
N Engl J Med, 2016 Dec 14; 375(23). PMID: 27959684    Free PMC article.
Highly Cited.
Macrophages and therapeutic resistance in cancer.
Brian Ruffell, Lisa M Coussens.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858805    Free PMC article.
Highly Cited. Review.
Endogenous T-Cell Therapy: Clinical Experience.
Cassian Yee, Greg Lizee, Aaron J Schueneman.
Cancer J, 2015 Nov 21; 21(6). PMID: 26588682
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
J E Darnell, I M Kerr, G R Stark.
Science, 1994 Jun 03; 264(5164). PMID: 8197455
Highly Cited. Review.
The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus).
W B Coley.
Proc R Soc Med, 1910 Jan 01; 3(Surg Sect). PMID: 19974799    Free PMC article.
Highly Cited.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, +16 authors, Stephan A Grupp.
N Engl J Med, 2014 Oct 16; 371(16). PMID: 25317870    Free PMC article.
Highly Cited.
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei-Ling Chen, Whijae Roh, +41 authors, Jennifer A Wargo.
Cancer Discov, 2016 Jun 16; 6(8). PMID: 27301722    Free PMC article.
Highly Cited.
Genetic evolution of T-cell resistance in the course of melanoma progression.
Antje Sucker, Fang Zhao, +16 authors, Annette Paschen.
Clin Cancer Res, 2014 Oct 09; 20(24). PMID: 25294904    Free PMC article.
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
Dung T Le, Eric Lutz, +8 authors, Daniel A Laheru.
J Immunother, 2013 Aug 09; 36(7). PMID: 23924790    Free PMC article.
Highly Cited.
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.
Melissa M Berrien-Elliott, Stephanie R Jackson, +6 authors, Ryan M Teague.
Cancer Res, 2012 Nov 29; 73(2). PMID: 23188506    Free PMC article.
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Stefani Spranger, Riyue Bao, Thomas F Gajewski.
Nature, 2015 May 15; 523(7559). PMID: 25970248
Highly Cited.
Mechanisms of type-I- and type-II-interferon-mediated signalling.
Leonidas C Platanias.
Nat Rev Immunol, 2005 May 03; 5(5). PMID: 15864272
Highly Cited. Review.
CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
Margaret Gil, Marcin P Komorowski, +5 authors, Danuta Kozbor.
J Immunol, 2014 Oct 17; 193(10). PMID: 25320277    Free PMC article.
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
Richard C Koya, Stephen Mok, +8 authors, Antoni Ribas.
Cancer Res, 2012 Jun 14; 72(16). PMID: 22693252    Free PMC article.
Highly Cited.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, +23 authors, Antoni Ribas.
Nature, 2014 Nov 28; 515(7528). PMID: 25428505    Free PMC article.
Highly Cited.
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Esra A Akbay, Shohei Koyama, +24 authors, Kwok-Kin Wong.
Cancer Discov, 2013 Oct 01; 3(12). PMID: 24078774    Free PMC article.
Highly Cited.
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
Dennie T Frederick, Adriano Piris, +18 authors, Jennifer A Wargo.
Clin Cancer Res, 2013 Jan 12; 19(5). PMID: 23307859    Free PMC article.
Highly Cited.
Adaptive Immune Resistance: How Cancer Protects from Immune Attack.
Antoni Ribas.
Cancer Discov, 2015 Aug 15; 5(9). PMID: 26272491    Free PMC article.
Highly Cited. Review.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
TGFbeta in Cancer.
Joan Massagué.
Cell, 2008 Jul 30; 134(2). PMID: 18662538    Free PMC article.
Highly Cited. Review.
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Weiyi Peng, Jie Qing Chen, +41 authors, Patrick Hwu.
Cancer Discov, 2015 Dec 10; 6(2). PMID: 26645196    Free PMC article.
Highly Cited.
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
Gregory L Beatty, Andrew R Haas, +9 authors, Carl H June.
Cancer Immunol Res, 2014 Mar 01; 2(2). PMID: 24579088    Free PMC article.
Highly Cited.
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Yu Zhu, Brett L Knolhoff, +7 authors, David G DeNardo.
Cancer Res, 2014 Aug 02; 74(18). PMID: 25082815    Free PMC article.
Highly Cited.
Emerging concepts of T cell metabolism as a target of immunotherapy.
Chih-Hao Chang, Erika L Pearce.
Nat Immunol, 2016 Mar 24; 17(4). PMID: 27002844    Free PMC article.
Highly Cited.
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.
Claire Vanpouille-Box, Julie M Diamond, +5 authors, Sandra Demaria.
Cancer Res, 2015 Apr 11; 75(11). PMID: 25858148    Free PMC article.
Highly Cited.
History of myeloid-derived suppressor cells.
James E Talmadge, Dmitry I Gabrilovich.
Nat Rev Cancer, 2013 Sep 26; 13(10). PMID: 24060865    Free PMC article.
Highly Cited. Review.
Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
Carsten T Viehl, Todd T Moore, +5 authors, David C Linehan.
Ann Surg Oncol, 2006 Sep 05; 13(9). PMID: 16952047
Regulatory T cells and Foxp3.
Alexander Y Rudensky.
Immunol Rev, 2011 Apr 15; 241(1). PMID: 21488902    Free PMC article.
Highly Cited. Review.
Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming.
Michael D Buck, David O'Sullivan, +16 authors, Erika L Pearce.
Cell, 2016 Jun 14; 166(1). PMID: 27293185    Free PMC article.
Highly Cited.
Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
Li-Xin Wang, Zhen-Yang Mei, +17 authors, Li Yu.
PLoS One, 2013 May 15; 8(5). PMID: 23671644    Free PMC article.
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
Steven L Highfill, Yongzhi Cui, +5 authors, Crystal L Mackall.
Sci Transl Med, 2014 May 23; 6(237). PMID: 24848257    Free PMC article.
Highly Cited.
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Siwen Hu-Lieskovan, Stephen Mok, +8 authors, Antoni Ribas.
Sci Transl Med, 2015 Mar 20; 7(279). PMID: 25787767    Free PMC article.
Highly Cited.
Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.
Xuesong Wu, Brian C Schulte, +5 authors, Sam T Hwang.
J Invest Dermatol, 2014 May 02; 134(11). PMID: 24780929
Macrophage depletion reduces postsurgical tumor recurrence and metastatic growth in a spontaneous murine model of melanoma.
Muly Tham, Karen Khoo, +4 authors, Jean-Pierre Abastado.
Oncotarget, 2015 Mar 13; 6(26). PMID: 25762633    Free PMC article.
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
Igor Puzanov, Mohammed M Milhem, +9 authors, Robert H I Andtbacka.
J Clin Oncol, 2016 Jun 15; 34(22). PMID: 27298410    Free PMC article.
Highly Cited.
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
M F Krummel, J P Allison.
J Exp Med, 1995 Aug 01; 182(2). PMID: 7543139    Free PMC article.
Highly Cited.
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Rikke B Holmgaard, Dmitriy Zamarin, +2 authors, James P Allison.
J Exp Med, 2013 Jun 12; 210(7). PMID: 23752227    Free PMC article.
Highly Cited.
CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.
Bruno G Leclerc, Roxanne Charlebois, +4 authors, John Stagg.
Clin Cancer Res, 2015 Aug 09; 22(1). PMID: 26253870
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
Begoña Comin-Anduix, Thinle Chodon, +7 authors, Antoni Ribas.
Clin Cancer Res, 2010 Dec 21; 16(24). PMID: 21169256    Free PMC article.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Steven A Rosenberg, James C Yang, +12 authors, Mark E Dudley.
Clin Cancer Res, 2011 Apr 19; 17(13). PMID: 21498393    Free PMC article.
Highly Cited.
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.
Chao Ma, Ann F Cheung, +12 authors, James R Heath.
Cancer Discov, 2013 Mar 23; 3(4). PMID: 23519018    Free PMC article.
Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
William L Redmond, Stefanie N Linch, Melissa J Kasiewicz.
Cancer Immunol Res, 2014 Apr 30; 2(2). PMID: 24778278    Free PMC article.
Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions.
Rona Ortenberg, Yair Sapir, +10 authors, Gal Markel.
Mol Cancer Ther, 2012 Apr 03; 11(6). PMID: 22466331
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
Olivier De Henau, Matthew Rausch, +21 authors, Taha Merghoub.
Nature, 2016 Nov 10; 539(7629). PMID: 27828943    Free PMC article.
Highly Cited.
Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.
De-Kuan Chang, Jianhua Sui, +11 authors, Wayne A Marasco.
Mol Cancer Ther, 2012 Aug 08; 11(11). PMID: 22869555    Free PMC article.
Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.
Stephen Mok, Richard C Koya, +7 authors, Antoni Ribas.
Cancer Res, 2013 Nov 20; 74(1). PMID: 24247719    Free PMC article.
Highly Cited.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.
Brian Ruffell, Debbie Chang-Strachan, +7 authors, Lisa M Coussens.
Cancer Cell, 2014 Dec 03; 26(5). PMID: 25446896    Free PMC article.
Highly Cited.
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
Sherene Loi, Sandra Pommey, +4 authors, John Stagg.
Proc Natl Acad Sci U S A, 2013 Jun 19; 110(27). PMID: 23776241    Free PMC article.
Highly Cited.
CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
Martin Turcotte, Kathleen Spring, +12 authors, John Stagg.
Cancer Res, 2015 Sep 13; 75(21). PMID: 26363007
Highly Cited.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Kristin J Lastwika, Willie Wilson, +10 authors, Phillip A Dennis.
Cancer Res, 2015 Dec 08; 76(2). PMID: 26637667
Highly Cited.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, +16 authors, Philippe Armand.
N Engl J Med, 2014 Dec 09; 372(4). PMID: 25482239    Free PMC article.
Highly Cited.
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
V Bronte, M Wang, +4 authors, N P Restifo.
J Immunol, 1998 Nov 20; 161(10). PMID: 9820504    Free PMC article.
Highly Cited.
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.
Li Yang, Laura M DeBusk, +6 authors, P Charles Lin.
Cancer Cell, 2004 Oct 19; 6(4). PMID: 15488763
Highly Cited.
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.
Andrew T Parsa, James S Waldron, +10 authors, Russell O Pieper.
Nat Med, 2006 Dec 13; 13(1). PMID: 17159987
Highly Cited.
Adoptive T-Cell Therapy for Cancer.
James C Yang, Steven A Rosenberg.
Adv Immunol, 2016 Mar 01; 130. PMID: 26923004    Free PMC article.
Highly Cited. Review.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Paul F Robbins, Richard A Morgan, +18 authors, Steven A Rosenberg.
J Clin Oncol, 2011 Feb 02; 29(7). PMID: 21282551    Free PMC article.
Highly Cited.
Tumor-associated macrophages in cancers.
W Hu, X Li, +3 authors, C Wu.
Clin Transl Oncol, 2015 Aug 13; 18(3). PMID: 26264497
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
Rituparna Das, Rakesh Verma, +8 authors, Kavita M Dhodapkar.
J Immunol, 2014 Dec 30; 194(3). PMID: 25539810    Free PMC article.
Highly Cited.
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, +3 authors, Ana C Anderson.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819927    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
Carola H Ries, Michael A Cannarile, +24 authors, Dominik Rüttinger.
Cancer Cell, 2014 Jun 06; 25(6). PMID: 24898549
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Ayelet Sivan, Leticia Corrales, +9 authors, Thomas F Gajewski.
Science, 2015 Nov 07; 350(6264). PMID: 26541606    Free PMC article.
Highly Cited.
Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Michael S Rooney, Sachet A Shukla, +2 authors, Nir Hacohen.
Cell, 2015 Jan 17; 160(1-2). PMID: 25594174    Free PMC article.
Highly Cited.
Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3',5'-monophosphate and phosphatases.
Hong Zhang, David M Conrad, +3 authors, David W Hoskin.
J Immunol, 2004 Jul 09; 173(2). PMID: 15240680
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.
Blanca Homet Moreno, Stephen Mok, +2 authors, Antoni Ribas.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622011    Free PMC article.
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
Lars A Ormandy, Tina Hillemann, +3 authors, Firouzeh Korangy.
Cancer Res, 2005 Mar 23; 65(6). PMID: 15781662
Highly Cited.
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Ana C Anderson, Nicole Joller, Vijay K Kuchroo.
Immunity, 2016 May 19; 44(5). PMID: 27192565    Free PMC article.
Highly Cited. Review.
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.
Samantha Solito, Erika Falisi, +11 authors, Susanna Mandruzzato.
Blood, 2011 Jul 08; 118(8). PMID: 21734236    Free PMC article.
Highly Cited.
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
Ilona Kryczek, Linhua Zou, +12 authors, Weiping Zou.
J Exp Med, 2006 Apr 12; 203(4). PMID: 16606666    Free PMC article.
Highly Cited.
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.
Dong-Ming Kuang, Qiyi Zhao, +4 authors, Limin Zheng.
J Exp Med, 2009 May 20; 206(6). PMID: 19451266    Free PMC article.
Highly Cited.
Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma.
Diana Y L Tang, Robert A Ellis, Penny E Lovat.
Front Oncol, 2016 Nov 25; 6. PMID: 27882308    Free PMC article.
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.
R Dixon Dorand, Joseph Nthale, +9 authors, Agne Petrosiute.
Science, 2016 Jul 28; 353(6297). PMID: 27463676    Free PMC article.
Highly Cited.
4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Robert E Miller, Jon Jones, +4 authors, David H Lynch.
J Immunol, 2002 Aug 08; 169(4). PMID: 12165501
Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
William L Redmond, Michael J Gough, +2 authors, Andrew D Weinberg.
J Immunol, 2007 Nov 21; 179(11). PMID: 18025166
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Daisuke Sugiyama, Hiroyoshi Nishikawa, +10 authors, Shimon Sakaguchi.
Proc Natl Acad Sci U S A, 2013 Oct 16; 110(44). PMID: 24127572    Free PMC article.
Highly Cited.
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.
C M D'Urso, Z G Wang, +3 authors, S Ferrone.
J Clin Invest, 1991 Jan 01; 87(1). PMID: 1898655    Free PMC article.
Highly Cited.
Innate and adaptive immune cells in the tumor microenvironment.
Thomas F Gajewski, Hans Schreiber, Yang-Xin Fu.
Nat Immunol, 2013 Sep 21; 14(10). PMID: 24048123    Free PMC article.
Highly Cited. Review.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
CD73: A potential biomarker for anti-PD-1 therapy.
Paul A Beavis, Clare Y Slaney, +5 authors, Phillip K Darcy.
Oncoimmunology, 2015 Oct 10; 4(11). PMID: 26451321    Free PMC article.
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.
James S Wilmott, Georgina V Long, +6 authors, Richard A Scolyer.
Clin Cancer Res, 2011 Dec 14; 18(5). PMID: 22156613
Highly Cited.
Targeting tumor-associated macrophages as a novel strategy against breast cancer.
Yunping Luo, He Zhou, +8 authors, Rong Xiang.
J Clin Invest, 2006 Jul 25; 116(8). PMID: 16862213    Free PMC article.
Highly Cited.
Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
Krithika N Kodumudi, Amy Weber, Amod A Sarnaik, Shari Pilon-Thomas.
J Immunol, 2012 Oct 27; 189(11). PMID: 23100512    Free PMC article.
Chimeric antigen receptors: driving immunology towards synthetic biology.
Michel Sadelain.
Curr Opin Immunol, 2016 Jul 04; 41. PMID: 27372731    Free PMC article.
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Chengwen Liu, Weiyi Peng, +18 authors, Patrick Hwu.
Clin Cancer Res, 2012 Dec 04; 19(2). PMID: 23204132    Free PMC article.
Highly Cited.
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.
Elena Sotillo, David M Barrett, +27 authors, Andrei Thomas-Tikhonenko.
Cancer Discov, 2015 Nov 01; 5(12). PMID: 26516065    Free PMC article.
Highly Cited.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
G J Freeman, A J Long, +16 authors, T Honjo.
J Exp Med, 2000 Oct 04; 192(7). PMID: 11015443    Free PMC article.
Highly Cited.
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Keisuke Kataoka, Yuichi Shiraishi, +41 authors, Seishi Ogawa.
Nature, 2016 Jun 10; 534(7607). PMID: 27281199
Highly Cited.
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Sergio A Quezada, Karl S Peggs, Michael A Curran, James P Allison.
J Clin Invest, 2006 Jun 17; 116(7). PMID: 16778987    Free PMC article.
Highly Cited.
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Zachary A Cooper, Vikram R Juneja, +12 authors, Jennifer A Wargo.
Cancer Immunol Res, 2014 Jun 07; 2(7). PMID: 24903021    Free PMC article.
Highly Cited.
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Jianjun Gao, Lewis Zhichang Shi, +13 authors, Padmanee Sharma.
Cell, 2016 Sep 27; 167(2). PMID: 27667683    Free PMC article.
Highly Cited.
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
Edmund K Moon, Liang-Chuan Wang, +11 authors, Steven M Albelda.
Clin Cancer Res, 2014 Jun 13; 20(16). PMID: 24919573    Free PMC article.
Highly Cited.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, +26 authors, BRIM-3 Study Group.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639808    Free PMC article.
Highly Cited.
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis.
Jean-Jacques Lebrun.
ISRN Mol Biol, 2012 Jan 01; 2012. PMID: 27340590    Free PMC article.
Highly Cited. Review.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber, Sandra P D'Angelo, +25 authors, James Larkin.
Lancet Oncol, 2015 Mar 22; 16(4). PMID: 25795410
Highly Cited.
Anti-CD73 therapy impairs tumor angiogenesis.
Bertrand Allard, Martin Turcotte, +3 authors, John Stagg.
Int J Cancer, 2013 Aug 29; 134(6). PMID: 23982901
A new member of the immunoglobulin superfamily--CTLA-4.
J F Brunet, F Denizot, +4 authors, P Golstein.
Nature, 1987 Jul 16; 328(6127). PMID: 3496540
Highly Cited.
Engineered T cells: the promise and challenges of cancer immunotherapy.
Andrew D Fesnak, Carl H June, Bruce L Levine.
Nat Rev Cancer, 2016 Aug 24; 16(9). PMID: 27550819    Free PMC article.
Highly Cited. Review.
CEACAM1: contact-dependent control of immunity.
Scott D Gray-Owen, Richard S Blumberg.
Nat Rev Immunol, 2006 May 26; 6(6). PMID: 16724098
Highly Cited. Review.
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.
Dan D Vo, Robert M Prins, +12 authors, Antoni Ribas.
Cancer Res, 2009 Oct 29; 69(22). PMID: 19861533    Free PMC article.
Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses.
Rebecca R Laborde, Yi Lin, +2 authors, Allan B Dietz.
Front Immunol, 2014 Apr 29; 5. PMID: 24772111    Free PMC article.
Macrophage regulation of tumor responses to anticancer therapies.
Michele De Palma, Claire E Lewis.
Cancer Cell, 2013 Mar 23; 23(3). PMID: 23518347
Highly Cited. Review.
CD25+ CD4+ regulatory T-cells in cancer.
David C Linehan, Peter S Goedegebuure.
Immunol Res, 2005 Aug 18; 32(1-3). PMID: 16106066
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Antoni Ribas, Igor Puzanov, +33 authors, Adil Daud.
Lancet Oncol, 2015 Jun 28; 16(8). PMID: 26115796    Free PMC article.
Highly Cited.
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Omid Hamid, Henrik Schmidt, +9 authors, David Berman.
J Transl Med, 2011 Nov 30; 9. PMID: 22123319    Free PMC article.
Highly Cited.
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
Stefani Spranger, Holly K Koblish, +3 authors, Thomas F Gajewski.
J Immunother Cancer, 2014 May 16; 2. PMID: 24829760    Free PMC article.
Highly Cited.
Regulatory T cells and immune tolerance.
Shimon Sakaguchi, Tomoyuki Yamaguchi, Takashi Nomura, Masahiro Ono.
Cell, 2008 May 31; 133(5). PMID: 18510923
Highly Cited. Review.
A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells.
Chao Ma, Rong Fan, +9 authors, James R Heath.
Nat Med, 2011 May 24; 17(6). PMID: 21602800    Free PMC article.
Highly Cited.
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.
Lieping Chen.
Nat Rev Immunol, 2004 May 04; 4(5). PMID: 15122199
Highly Cited. Review.
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
D J Hicklin, Z Wang, +3 authors, S Ferrone.
J Clin Invest, 1998 Jun 24; 101(12). PMID: 9637706    Free PMC article.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, +18 authors, Paul B Chapman.
Lancet, 2012 Jun 28; 380(9839). PMID: 22735384
Highly Cited.
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.
Robert Wesolowski, Joseph Markowitz, William E Carson.
J Immunother Cancer, 2013 Jan 01; 1. PMID: 24829747    Free PMC article.
Highly Cited. Review.
Monitoring immune responses in the tumor microenvironment.
Jennifer A Wargo, Sangeetha M Reddy, Alexandre Reuben, Padmanee Sharma.
Curr Opin Immunol, 2016 May 31; 41. PMID: 27240055    Free PMC article.
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
Nienke van Rooij, Marit M van Buuren, +14 authors, Ton N Schumacher.
J Clin Oncol, 2013 Sep 18; 31(32). PMID: 24043743    Free PMC article.
Highly Cited.
Tumor-associated macrophages as major players in the tumor microenvironment.
Theerawut Chanmee, Pawared Ontong, Kenjiro Konno, Naoki Itano.
Cancers (Basel), 2014 Aug 16; 6(3). PMID: 25125485    Free PMC article.
Highly Cited. Review.
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
James Larkin, Christopher D Lao, +4 authors, Jedd D Wolchok.
JAMA Oncol, 2015 Jul 17; 1(4). PMID: 26181250
Highly Cited.
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.
H Dong, G Zhu, K Tamada, L Chen.
Nat Med, 1999 Dec 02; 5(12). PMID: 10581077
Highly Cited.
PI3Kγ is a molecular switch that controls immune suppression.
Megan M Kaneda, Karen S Messer, +20 authors, Judith A Varner.
Nature, 2016 Nov 01; 539(7629). PMID: 27642729    Free PMC article.
Highly Cited.
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
John Stagg, Upulie Divisekera, +5 authors, Mark J Smyth.
Proc Natl Acad Sci U S A, 2010 Jan 19; 107(4). PMID: 20080644    Free PMC article.
Highly Cited.
A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells.
M H Kaplan, A L Wurster, M J Grusby.
J Exp Med, 1998 Sep 22; 188(6). PMID: 9743537    Free PMC article.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, +19 authors, Levi A Garraway.
Science, 2015 Sep 12; 350(6257). PMID: 26359337    Free PMC article.
Highly Cited.
Differential regulation of carcinoembryonic antigen and biliary glycoprotein by gamma-interferon.
H Takahashi, Y Okai, +2 authors, J E Shively.
Cancer Res, 1993 Apr 01; 53(7). PMID: 8453631
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, +24 authors, Robert D Schreiber.
Nature, 2014 Nov 28; 515(7528). PMID: 25428507    Free PMC article.
Highly Cited.
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
Jason Roszik, Lauren E Haydu, +25 authors, Scott E Woodman.
BMC Med, 2016 Oct 26; 14(1). PMID: 27776519    Free PMC article.
Highly Cited.
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
Taku Okazaki, Shunsuke Chikuma, +2 authors, Tasuku Honjo.
Nat Immunol, 2013 Nov 19; 14(12). PMID: 24240160
Highly Cited. Review.
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.
Li Yang, Jianhua Huang, +8 authors, Harold L Moses.
Cancer Cell, 2008 Jan 03; 13(1). PMID: 18167337    Free PMC article.
Highly Cited.
CANCER IMMUNOLOGY. The "cancer immunogram".
Christian U Blank, John B Haanen, Antoni Ribas, Ton N Schumacher.
Science, 2016 May 07; 352(6286). PMID: 27151852
Highly Cited.
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
Leticia Corrales, Laura Hix Glickman, +10 authors, Thomas F Gajewski.
Cell Rep, 2015 May 12; 11(7). PMID: 25959818    Free PMC article.
Highly Cited.
Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer.
Run-Long Lin, Lu-Jun Zhao.
Cancer Biol Med, 2016 Jan 19; 12(4). PMID: 26779375    Free PMC article.
MYC regulates the antitumor immune response through CD47 and PD-L1.
Stephanie C Casey, Ling Tong, +8 authors, Dean W Felsher.
Science, 2016 Mar 12; 352(6282). PMID: 26966191    Free PMC article.
Highly Cited.
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A Akbay, +23 authors, Peter S Hammerman.
Nat Commun, 2016 Feb 18; 7. PMID: 26883990    Free PMC article.
Highly Cited.
Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber.
Science, 2015 Apr 04; 348(6230). PMID: 25838375
Highly Cited. Review.
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.
Sherille D Bradley, Zeming Chen, +12 authors, Gregory Lizée.
Cancer Immunol Res, 2015 Mar 22; 3(6). PMID: 25795007    Free PMC article.
Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas.
Jason M Fritz, Meredith A Tennis, +9 authors, Lori D Dwyer-Nield.
Front Immunol, 2014 Dec 17; 5. PMID: 25505466    Free PMC article.
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Janis M Taube, Alison Klein, +7 authors, Robert A Anders.
Clin Cancer Res, 2014 Apr 10; 20(19). PMID: 24714771    Free PMC article.
Highly Cited.
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.
Belal Chaudhary, Eyad Elkord.
Vaccines (Basel), 2016 Aug 12; 4(3). PMID: 27509527    Free PMC article.
Highly Cited. Review.
Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis.
Deepak Mittal, Debottam Sinha, +9 authors, Mark J Smyth.
Cancer Res, 2016 May 26; 76(15). PMID: 27221704
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Jason Madore, Ricardo E Vilain, +9 authors, Richard A Scolyer.
Pigment Cell Melanoma Res, 2014 Dec 06; 28(3). PMID: 25477049
Highly Cited.
Immunological surveillance in neoplasia.
F M Burnet.
Transplant Rev, 1971 Jan 01; 7. PMID: 5146537
Highly Cited.
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, +15 authors, Roger S Lo.
Cell, 2016 Mar 22; 165(1). PMID: 26997480    Free PMC article.
Highly Cited.
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Christiane Meyer, Laurène Cagnon, +6 authors, Daniel E Speiser.
Cancer Immunol Immunother, 2013 Dec 21; 63(3). PMID: 24357148
Highly Cited.
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.
V Shankaran, H Ikeda, +4 authors, R D Schreiber.
Nature, 2001 Apr 27; 410(6832). PMID: 11323675
Highly Cited.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
Janis M Taube, Robert A Anders, +8 authors, Lieping Chen.
Sci Transl Med, 2012 Mar 31; 4(127). PMID: 22461641    Free PMC article.
Highly Cited.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
Michael Kalos, Bruce L Levine, +4 authors, Carl H June.
Sci Transl Med, 2011 Aug 13; 3(95). PMID: 21832238    Free PMC article.
Highly Cited.
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
N P Restifo, F M Marincola, +3 authors, S A Rosenberg.
J Natl Cancer Inst, 1996 Jan 17; 88(2). PMID: 8537970    Free PMC article.
Highly Cited.
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, +26 authors, Antoni Ribas.
N Engl J Med, 2016 Jul 20; 375(9). PMID: 27433843    Free PMC article.
Highly Cited.
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, +10 authors, Lieping Chen.
Nat Med, 2002 Jul 02; 8(8). PMID: 12091876
Highly Cited.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Joseph L Benci, Bihui Xu, +16 authors, Andy J Minn.
Cell, 2016 Dec 03; 167(6). PMID: 27912061    Free PMC article.
Highly Cited.
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
Marco Ruella, David M Barrett, +18 authors, Saar Gill.
J Clin Invest, 2016 Aug 30; 126(10). PMID: 27571406    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin, Jesse M Zaretsky, +24 authors, Antoni Ribas.
Cancer Discov, 2016 Dec 03; 7(2). PMID: 27903500    Free PMC article.
Highly Cited.
CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism.
Takatoku Oida, Xingmin Zhang, +4 authors, Howard L Weiner.
J Immunol, 2003 Feb 21; 170(5). PMID: 12594277
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Daniel Sanghoon Shin, Antoni Ribas.
Curr Opin Immunol, 2015 Jan 27; 33. PMID: 25621841
Highly Cited. Review.
Molecular genetic and immunotherapeutic targets in metastatic melanoma.
C Melis, A Rogiers, O Bechter, Joost J van den Oord.
Virchows Arch, 2017 Mar 31; 471(2). PMID: 28357489
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.
Leanne G Ahronian, Ryan B Corcoran.
Genome Med, 2017 Apr 23; 9(1). PMID: 28431544    Free PMC article.
Hallmarks of response to immune checkpoint blockade.
Alexandria P Cogdill, Miles C Andrews, Jennifer A Wargo.
Br J Cancer, 2017 May 20; 117(1). PMID: 28524159    Free PMC article.
Highly Cited. Review.
In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade.
Eric Bartee, Zihai Li.
Exp Hematol Oncol, 2017 May 27; 6. PMID: 28546884    Free PMC article.
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.
Zong Sheng Guo, Zuqiang Liu, +5 authors, David L Bartlett.
Front Immunol, 2017 May 31; 8. PMID: 28555136    Free PMC article.
ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Giulia Cesi, Geoffroy Walbrecq, +2 authors, Claude Haan.
Mol Cancer, 2017 Jun 10; 16(1). PMID: 28595656    Free PMC article.
New insights into the role of EMT in tumor immune escape.
Stéphane Terry, Pierre Savagner, +4 authors, Salem Chouaib.
Mol Oncol, 2017 Jun 15; 11(7). PMID: 28614624    Free PMC article.
Highly Cited. Review.
Epithelial-to-Mesenchymal Transition in the Pathogenesis and Therapy of Head and Neck Cancer.
Julia Thierauf, Johannes Adrian Veit, Jochen Hess.
Cancers (Basel), 2017 Jul 04; 9(7). PMID: 28671620    Free PMC article.
Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.
Jie Yin, James M Markert, Jianmei W Leavenworth.
Front Oncol, 2017 Jul 12; 7. PMID: 28695111    Free PMC article.
The immune contexture in cancer prognosis and treatment.
Wolf H Fridman, Laurence Zitvogel, Catherine Sautès-Fridman, Guido Kroemer.
Nat Rev Clin Oncol, 2017 Jul 26; 14(12). PMID: 28741618
Highly Cited. Review.
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.
Claire Vanpouille-Box, Silvia C Formenti, Sandra Demaria.
Clin Cancer Res, 2017 Jul 29; 24(2). PMID: 28751442    Free PMC article.
Highly Cited. Review.
Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.
Namit Holay, Youra Kim, Patrick Lee, Shashi Gujar.
Front Immunol, 2017 Jul 29; 8. PMID: 28751892    Free PMC article.
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.
Dylan J Martini, Aly-Khan A Lalani, +5 authors, Toni K Choueiri.
J Immunother Cancer, 2017 Aug 16; 5(1). PMID: 28807048    Free PMC article.
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.
Alejandro Jiménez-Sánchez, Danish Memon, +16 authors, Martin L Miller.
Cell, 2017 Aug 26; 170(5). PMID: 28841418    Free PMC article.
Highly Cited.
Adenosine checkpoint agent blazes a trail, joins immunotherapy roster.
Ken Garber.
Nat Biotechnol, 2017 Sep 13; 35(9). PMID: 28898225
Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Matthew J Pianko, Alison J Moskowitz, Alexander M Lesokhin.
Clin Cancer Res, 2017 Sep 14; 24(5). PMID: 28899972    Free PMC article.
Targets for immunotherapy of liver cancer.
Tim F Greten, Bruno Sangro.
J Hepatol, 2017 Sep 20;. PMID: 28923358    Free PMC article.
Roles for Innate Immunity in Combination Immunotherapies.
Kelly D Moynihan, Darrell J Irvine.
Cancer Res, 2017 Sep 21; 77(19). PMID: 28928130    Free PMC article.
Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.
Haifa Shen, Tong Sun, +4 authors, Mauro Ferrari.
Semin Immunol, 2017 Sep 28; 34. PMID: 28947107    Free PMC article.
Checkpoint Inhibitors: Applications for Autoimmunity.
Anna S Tocheva, Adam Mor.
Curr Allergy Asthma Rep, 2017 Sep 29; 17(10). PMID: 28956259    Free PMC article.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.
Paolo A Ascierto, Bruno Daniele, +5 authors, Sandro Pignata.
J Transl Med, 2017 Oct 13; 15(1). PMID: 29020960    Free PMC article.
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.
Isobel S Okoye, Michael Houghton, +2 authors, Shokrollah Elahi.
Front Immunol, 2017 Oct 17; 8. PMID: 29033936    Free PMC article.
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
Russell W Jenkins, Amir R Aref, +81 authors, David A Barbie.
Cancer Discov, 2017 Nov 05; 8(2). PMID: 29101162    Free PMC article.
Highly Cited.
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.
Lidia M Yshii, Reinhard Hohlfeld, Roland S Liblau.
Nat Rev Neurol, 2017 Nov 07; 13(12). PMID: 29104289
The combination of checkpoint immunotherapy and targeted therapy in cancer.
Niki Karachaliou, Maria Gonzalez-Cao, +4 authors, Rafael Rosell.
Ann Transl Med, 2017 Nov 09; 5(19). PMID: 29114546    Free PMC article.
Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade.
Alejandro López-Soto, Segundo Gonzalez, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 11; 6(10). PMID: 29123961    Free PMC article.
Conventional CD4+ T cells present bacterial antigens to induce cytotoxic and memory CD8+ T cell responses.
Aránzazu Cruz-Adalia, Guillermo Ramirez-Santiago, +10 authors, Esteban Veiga.
Nat Commun, 2017 Nov 18; 8(1). PMID: 29147022    Free PMC article.
CD103+ cells at the forefront of anticancer immunity.
Claire Vanpouille-Box, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147613    Free PMC article.
Blinatumomab bridges the gap between leukemia and immunity.
Takahiro Yamazaki, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147620    Free PMC article.
Trial watch: Immune checkpoint blockers for cancer therapy.
Claire Vanpouille-Box, Claire Lhuillier, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147629    Free PMC article.
Highly Cited. Review.
Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.
Zhiqiang Guo, Yan Li, Dandan Zhang, Jiaying Ma.
Oncotarget, 2017 Nov 23; 8(52). PMID: 29163786    Free PMC article.
Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance.
Heinz Hammerlindl, Helmut Schaider.
J Cell Commun Signal, 2017 Dec 02; 12(1). PMID: 29192388    Free PMC article.
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Mariona Cabo, Rienk Offringa, +3 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Dec 07; 6(12). PMID: 29209572    Free PMC article.
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.
Abhishek D Garg, Sanket More, +6 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Dec 07; 6(12). PMID: 29209573    Free PMC article.
Highly Cited. Review.
Mitochondrial metabolism and cancer.
Paolo Ettore Porporato, Nicoletta Filigheddu, +2 authors, Lorenzo Galluzzi.
Cell Res, 2017 Dec 09; 28(3). PMID: 29219147    Free PMC article.
Highly Cited. Review.
Towards personalized, tumour-specific, therapeutic vaccines for cancer.
Zhuting Hu, Patrick A Ott, Catherine J Wu.
Nat Rev Immunol, 2017 Dec 12; 18(3). PMID: 29226910    Free PMC article.
Highly Cited. Review.
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Young Kwang Chae, Michael S Oh, Francis J Giles.
Oncologist, 2017 Dec 16; 23(4). PMID: 29242279    Free PMC article.
Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.
Eva Bräunlein, Angela M Krackhardt.
Front Immunol, 2017 Dec 19; 8. PMID: 29250075    Free PMC article.
Informatics for cancer immunotherapy.
J Hammerbacher, A Snyder.
Ann Oncol, 2017 Dec 19; 28(suppl_12). PMID: 29253114    Free PMC article.
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.
Claire Lhuillier, Claire Vanpouille-Box, +2 authors, Sandra Demaria.
Semin Cancer Biol, 2017 Dec 21; 52(Pt 2). PMID: 29258856    Free PMC article.
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Florie Bertrand, Anne Montfort, +9 authors, Bruno Ségui.
Nat Commun, 2017 Dec 24; 8(1). PMID: 29273790    Free PMC article.
Highly Cited.
Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.
Hassan Sadozai, Thomas Gruber, Robert Emil Hunger, Mirjam Schenk.
Front Immunol, 2017 Dec 26; 8. PMID: 29276510    Free PMC article.
The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion.
Marija Mojic, Kazuyoshi Takeda, Yoshihiro Hayakawa.
Int J Mol Sci, 2017 Dec 29; 19(1). PMID: 29283429    Free PMC article.
A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.
Deng Pan, Aya Kobayashi, +13 authors, Kai W Wucherpfennig.
Science, 2018 Jan 06; 359(6377). PMID: 29301958    Free PMC article.
Highly Cited.
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Diana Miao, Claire A Margolis, +23 authors, Eliezer M Van Allen.
Science, 2018 Jan 06; 359(6377). PMID: 29301960    Free PMC article.
Highly Cited.
FOXOs in cancer immunity: Knowns and unknowns.
Youcai Deng, Fangjie Wang, Tiffany Hughes, Jianhua Yu.
Semin Cancer Biol, 2018 Jan 09; 50. PMID: 29309928    Free PMC article.
Inhibitors of the PD-1 Pathway in Tumor Therapy.
Martin W LaFleur, Yuki Muroyama, Charles G Drake, Arlene H Sharpe.
J Immunol, 2018 Jan 10; 200(2). PMID: 29311378    Free PMC article.
Mechanisms of resistance to immune checkpoint inhibitors.
Russell W Jenkins, David A Barbie, Keith T Flaherty.
Br J Cancer, 2018 Jan 11; 118(1). PMID: 29319049    Free PMC article.
Highly Cited. Review.
Precision oncology in the age of integrative genomics.
Chandan Kumar-Sinha, Arul M Chinnaiyan.
Nat Biotechnol, 2018 Jan 11; 36(1). PMID: 29319699    Free PMC article.
Impact of oncogenic pathways on evasion of antitumour immune responses.
Stefani Spranger, Thomas F Gajewski.
Nat Rev Cancer, 2018 Jan 13; 18(3). PMID: 29326431    Free PMC article.
Highly Cited. Review.
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
Julia Boshuizen, Louise A Koopman, +17 authors, Paul W H I Parren.
Nat Med, 2018 Jan 16; 24(2). PMID: 29334371
Highly Cited.
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
Masoud F Tavazoie, Ilana Pollack, +21 authors, Sohail F Tavazoie.
Cell, 2018 Jan 18; 172(4). PMID: 29336888    Free PMC article.
Highly Cited.
Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.
Akihiro Hosoi, Kazuyoshi Takeda, +10 authors, Kazuhiro Kakimi.
Sci Rep, 2018 Jan 20; 8(1). PMID: 29348598    Free PMC article.
eIF2α phosphorylation is pathognomonic for immunogenic cell death.
Lucillia Bezu, Allan Sauvat, +10 authors, Guido Kroemer.
Cell Death Differ, 2018 Jan 24; 25(8). PMID: 29358668    Free PMC article.
Highly Cited.
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.
Tricia R Cottrell, Janis M Taube.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360727    Free PMC article.
Mechanisms of Resistance to PD-1 and PD-L1 Blockade.
Theodore S Nowicki, Siwen Hu-Lieskovan, Antoni Ribas.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360728    Free PMC article.
Highly Cited. Review.
Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses.
Chi-Ping Huang, Chi-Cheng Chen, Chih-Rong Shyr.
Cancer Cell Int, 2018 Jan 27; 18. PMID: 29371832    Free PMC article.
Radiation effects on antitumor immune responses: current perspectives and challenges.
Thomas Walle, Rafael Martinez Monge, +3 authors, Fernando Lecanda.
Ther Adv Med Oncol, 2018 Feb 01; 10. PMID: 29383033    Free PMC article.
Highly Cited. Review.
Predictive immune biomarkers: an unattainable chimera?
Anna Maria Trotta, Roberto Pacelli, Stefania Scala.
Cell Mol Immunol, 2018 Feb 06; 15(8). PMID: 29400708    Free PMC article.
From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Debra L Madden.
Curr Oncol Rep, 2018 Feb 08; 20(1). PMID: 29411148
A potential biomarker for anti-PD-1 immunotherapy.
Sangeeta Goswami, Sreyashi Basu, Padmanee Sharma.
Nat Med, 2018 Feb 08; 24(2). PMID: 29414936
DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation.
Qian Xiao, Jibo Wu, +14 authors, Dianqing Wu.
Nat Med, 2018 Feb 13; 24(3). PMID: 29431745    Free PMC article.
Highly Cited.
Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC).
Young Kwang Chae, Sangmin Chang, +6 authors, Marcelo Cruz.
Sci Rep, 2018 Feb 15; 8(1). PMID: 29440769    Free PMC article.
Highly Cited.
Harnessing the immune system in the battle against breast cancer.
Elizabeth S Nakasone, Sara A Hurvitz, Kelly E McCann.
Drugs Context, 2018 Feb 20; 7. PMID: 29456568    Free PMC article.
The Role of the Estrogen Pathway in the Tumor Microenvironment.
Natalie J Rothenberger, Ashwin Somasundaram, Laura P Stabile.
Int J Mol Sci, 2018 Feb 22; 19(2). PMID: 29463044    Free PMC article.
Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils.
Nathaniel Robichaud, Brian E Hsu, +16 authors, Nahum Sonenberg.
Proc Natl Acad Sci U S A, 2018 Feb 22; 115(10). PMID: 29463754    Free PMC article.
New developments in the management of head and neck cancer - impact of pembrolizumab.
Khalil Saleh, Roland Eid, +2 authors, Hampig Raphaël Kourie.
Ther Clin Risk Manag, 2018 Mar 03; 14. PMID: 29497306    Free PMC article.
Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma.
Divya Sekar, Luisa Govene, +5 authors, Andreas Weigert.
Int J Mol Sci, 2018 Mar 10; 19(3). PMID: 29518903    Free PMC article.
Cell-based molecularly targeted therapy: targeting oncoproteins with T cell receptor gene therapy.
Christian S Hinrichs.
J Clin Invest, 2018 Mar 13; 128(4). PMID: 29528339    Free PMC article.
A usable model of "decathlon winner" cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence.
Balraj Singh, Vanessa N Sarli, +2 authors, Anthony Lucci.
Oncotarget, 2018 Mar 16; 9(13). PMID: 29541397    Free PMC article.
Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Julian A Marin-Acevedo, Bhagirathbhai Dholaria, +3 authors, Yanyan Lou.
J Hematol Oncol, 2018 Mar 17; 11(1). PMID: 29544515    Free PMC article.
Highly Cited. Review.
Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
Benoît L Salomon, Mathieu Leclerc, +3 authors, José L Cohen.
Front Immunol, 2018 Mar 30; 9. PMID: 29593717    Free PMC article.
Echinococcus granulosus: Cure for Cancer Revisited.
Shiwanthi L Ranasinghe, Donald P McManus.
Front Med (Lausanne), 2018 Mar 30; 5. PMID: 29594121    Free PMC article.
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.
Shisuo Du, Neal McCall, +6 authors, Bo Lu.
Oncoimmunology, 2018 Apr 11; 7(4). PMID: 29632720    Free PMC article.
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Roberta Zappasodi, Taha Merghoub, Jedd D Wolchok.
Cancer Cell, 2018 Apr 11; 33(4). PMID: 29634946    Free PMC article.
Highly Cited. Review.
MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer.
Chenwei Pan, Luxia Xiang, +6 authors, Xuezhen Hu.
Cancer Cell Int, 2018 Apr 11; 18. PMID: 29636640    Free PMC article.
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima.
Front Oncol, 2018 Apr 13; 8. PMID: 29644214    Free PMC article.
Highly Cited. Review.
Macrophages: The Road Less Traveled, Changing Anticancer Therapy.
Jennifer L Guerriero.
Trends Mol Med, 2018 Apr 16; 24(5). PMID: 29655673    Free PMC article.
Highly Cited. Review.
Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy.
Brianne Cruickshank, Michael Giacomantonio, +3 authors, Shashi Gujar.
Front Immunol, 2018 Apr 19; 9. PMID: 29666625    Free PMC article.
Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors.
Luca Cassetta, Takanori Kitamura.
Front Cell Dev Biol, 2018 Apr 20; 6. PMID: 29670880    Free PMC article.
Highly Cited. Review.
Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
Stefania Orecchioni, Giovanna Talarico, +3 authors, Francesco Bertolini.
Br J Cancer, 2018 Apr 27; 118(10). PMID: 29695766    Free PMC article.
Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine.
Masaru Katoh.
J Thorac Dis, 2018 May 01; 10(3). PMID: 29708143    Free PMC article.
Cancer CRISPR Screens In Vivo.
Ryan D Chow, Sidi Chen.
Trends Cancer, 2018 May 02; 4(5). PMID: 29709259    Free PMC article.
Pro-tumoral immune cell alterations in wild type and Shb-deficient mice in response to 4T1 breast carcinomas.
Xiujuan Li, Kailash Singh, +6 authors, Michael Welsh.
Oncotarget, 2018 May 04; 9(27). PMID: 29721156    Free PMC article.
Mechanisms of Intrinsic Tumor Resistance to Immunotherapy.
John Rieth, Subbaya Subramanian.
Int J Mol Sci, 2018 May 05; 19(5). PMID: 29724044    Free PMC article.
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
Yayi He, Sangtian Liu, +3 authors, Daniel Chan.
Drug Des Devel Ther, 2018 May 08; 12. PMID: 29731605    Free PMC article.
Contemporary Approaches to In-Transit Melanoma.
Jennifer A Perone, Nellie Farrow, Douglas S Tyler, Georgia M Beasley.
J Oncol Pract, 2018 May 11; 14(5). PMID: 29746804    Free PMC article.
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.
Michael R Shafique, Lary A Robinson, Scott Antonia.
Cancer Manag Res, 2018 May 16; 10. PMID: 29760563    Free PMC article.
Programmable sequential mutagenesis by inducible Cpf1 crRNA array inversion.
Ryan D Chow, Hyunu Ray Kim, Sidi Chen.
Nat Commun, 2018 May 17; 9(1). PMID: 29765043    Free PMC article.
Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis.
Chong Wu, Huiheng Ning, +12 authors, Limin Zheng.
J Clin Invest, 2018 May 18; 128(8). PMID: 29771686    Free PMC article.
Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.
Miles C Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, Jennifer A Wargo.
Front Immunol, 2018 May 22; 9. PMID: 29780391    Free PMC article.
Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.
Anne Sophie Kubasch, Uwe Platzbecker.
Cancers (Basel), 2018 May 26; 10(6). PMID: 29795051    Free PMC article.
Current status and future directions of cancer immunotherapy.
Hongming Zhang, Jibei Chen.
J Cancer, 2018 May 29; 9(10). PMID: 29805703    Free PMC article.
Highly Cited. Review.
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
Peixin Dong, Ying Xiong, +7 authors, Noriaki Sakuragi.
Oncogene, 2018 Jun 02; 37(39). PMID: 29855617    Free PMC article.
Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Mathieu Rouanne, Mathieu Roumiguié, +7 authors, Yann Neuzillet.
World J Urol, 2018 Jun 02; 36(11). PMID: 29855698
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.
Mengjia Song, Xinfeng Chen, Liping Wang, Yi Zhang.
Chin J Cancer Res, 2018 Jun 05; 30(2). PMID: 29861603    Free PMC article.
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.
Arnav Mehta, Yeon Joo Kim, +8 authors, Antoni Ribas.
Cancer Discov, 2018 Jun 15; 8(8). PMID: 29899062    Free PMC article.
Highly Cited.
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Yi-Mi Wu, Marcin Cieślik, +18 authors, Arul M Chinnaiyan.
Cell, 2018 Jun 16; 173(7). PMID: 29906450    Free PMC article.
Highly Cited.
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
Yiting Wang, Huanbin Wang, +3 authors, Jie Xu.
Front Pharmacol, 2018 Jun 19; 9. PMID: 29910728    Free PMC article.
Highly Cited. Review.
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.
Aubhishek Zaman, Trever G Bivona.
Ann Transl Med, 2018 Jun 19; 6(9). PMID: 29911108    Free PMC article.
Melanoma treatment in review.
Beatriz Domingues, José Manuel Lopes, Paula Soares, Helena Pópulo.
Immunotargets Ther, 2018 Jun 21; 7. PMID: 29922629    Free PMC article.
Highly Cited. Review.
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.
Wanqiang Sheng, Martin W LaFleur, +13 authors, Yang Shi.
Cell, 2018 Jun 26; 174(3). PMID: 29937226    Free PMC article.
Highly Cited.
Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer.
Ena Arora, Muhammad Masab, +3 authors, Claudia Dourado.
Cureus, 2018 Jun 27; 10(4). PMID: 29942724    Free PMC article.
Exploring the links between cancer and placenta development.
Vincenzo Costanzo, Alberto Bardelli, Salvatore Siena, Sergio Abrignani.
Open Biol, 2018 Jun 29; 8(6). PMID: 29950452    Free PMC article.
Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
Guang-Tao Yu, Liang Mao, +8 authors, Zhi-Jun Sun.
Cell Mol Life Sci, 2018 Jun 30; 75(22). PMID: 29955905
Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Zachary J Brown, Su Jong Yu, +7 authors, Tim F Greten.
Cancer Immunol Immunother, 2018 Jul 01; 67(8). PMID: 29959458    Free PMC article.
Macrophage targeting: opening new possibilities for cancer immunotherapy.
Luca Cassetta, Takanori Kitamura.
Immunology, 2018 Jul 03; 155(3). PMID: 29963704    Free PMC article.
HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.
Laura Menotti, Elisa Avitabile, +3 authors, Gabriella Campadelli-Fiume.
Viruses, 2018 Jul 04; 10(7). PMID: 29966356    Free PMC article.
Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.
Su Yin Lim, Helen Rizos.
Mamm Genome, 2018 Jul 04; 29(11-12). PMID: 29968076    Free PMC article.
Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R.
Ying-Qiang Liu, Ya-Nan Wang, +14 authors, Jian Ding.
Acta Pharmacol Sin, 2018 Jul 04; 39(11). PMID: 29968849    Free PMC article.
Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity.
Iris Scherwitzl, Alicia Hurtado, +3 authors, Daniel Meruelo.
Mol Ther Oncolytics, 2018 Jul 11; 9. PMID: 29988525    Free PMC article.
A temporally dynamic Foxp3 autoregulatory transcriptional circuit controls the effector Treg programme.
David Bending, Alina Paduraru, +3 authors, Masahiro Ono.
EMBO J, 2018 Jul 12; 37(16). PMID: 29991564    Free PMC article.
Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
Geoffrey J Markowitz, Lauren S Havel, +10 authors, Vivek Mittal.
JCI Insight, 2018 Jul 13; 3(13). PMID: 29997286    Free PMC article.
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Alexander C Hopkins, Mark Yarchoan, +7 authors, Elizabeth M Jaffee.
JCI Insight, 2018 Jul 13; 3(13). PMID: 29997287    Free PMC article.
Highly Cited.
CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients.
Diane Goltz, Heidrun Gevensleben, +6 authors, Dimo Dietrich.
JCI Insight, 2018 Jul 13; 3(13). PMID: 29997292    Free PMC article.
Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Dipongkor Saha, Robert L Martuza, Samuel D Rabkin.
Immunotherapy, 2018 Jul 17; 10(9). PMID: 30008259    Free PMC article.
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
Limo Chen, Lixia Diao, +36 authors, Don L Gibbons.
Cancer Discov, 2018 Jul 18; 8(9). PMID: 30012853    Free PMC article.
Highly Cited.
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors.
Hui Yang, Kai Shen, +3 authors, Xuelei Ma.
Drug Des Devel Ther, 2018 Jul 18; 12. PMID: 30013326    Free PMC article.
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Douglas B Johnson, Jennifer Bordeaux, +22 authors, Naveen Dakappagari.
Clin Cancer Res, 2018 Jul 20; 24(21). PMID: 30021908    Free PMC article.
Recombinant Listeria promotes tumor rejection by CD8+ T cell-dependent remodeling of the tumor microenvironment.
Weiwen Deng, Victor Lira, +10 authors, Thomas W Dubensky.
Proc Natl Acad Sci U S A, 2018 Jul 25; 115(32). PMID: 30038013    Free PMC article.
Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy.
Claudius Melzig, Azadeh Fahim Golestaneh, +8 authors, Amir Abdollahi.
Oncotarget, 2018 Jul 26; 9(52). PMID: 30042828    Free PMC article.
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.
Yi-Long Wu, Chang-Li Wang, +53 authors, Wen-Zhao Zhong.
Transl Lung Cancer Res, 2018 Jul 28; 7(3). PMID: 30050780    Free PMC article.
Single-cell RNA-seq analysis identifies markers of resistance to targeted BRAF inhibitors in melanoma cell populations.
Yu-Jui Ho, Naishitha Anaparthy, +5 authors, Molly Gale Hammell.
Genome Res, 2018 Aug 01; 28(9). PMID: 30061114    Free PMC article.
Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade.
Kavita M Dhodapkar.
Front Immunol, 2018 Aug 01; 9. PMID: 30061902    Free PMC article.
Activation of phagocytosis by immune checkpoint blockade.
Chia-Wei Li, Yun-Ju Lai, Jennifer L Hsu, Mien-Chie Hung.
Front Med, 2018 Aug 01; 12(4). PMID: 30062558    Free PMC article.
Seeking Convergence and Cure with New Myeloma Therapies.
Priya Choudhry, Derek Galligan, Arun P Wiita.
Trends Cancer, 2018 Aug 02; 4(8). PMID: 30064664    Free PMC article.
Emerging strategies for combination checkpoint modulators in cancer immunotherapy.
Aleksandra Popovic, Elizabeth M Jaffee, Neeha Zaidi.
J Clin Invest, 2018 Aug 02; 128(8). PMID: 30067248    Free PMC article.
Highly Cited. Review.
Sno-derived RNAs are prevalent molecular markers of cancer immunity.
Ryan D Chow, Sidi Chen.
Oncogene, 2018 Aug 04; 37(50). PMID: 30072739    Free PMC article.
Making the right calls in precision oncology.
Kathryn D Bungartz, Kristen Lalowski, Sheryl K Elkin.
Nat Biotechnol, 2018 Aug 07; 36(8). PMID: 30080824
Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
Angela Rita Elia, Sara Caputo, Matteo Bellone.
Front Immunol, 2018 Aug 16; 9. PMID: 30108594    Free PMC article.
Intratumoral immune-biomarkers and mismatch repair status in leiyomyosarcoma -potential predictive markers for adjuvant treatment: a pilot study.
Jonathan E Cohen, Feras Eleyan, +2 authors, Daniela Katz.
Oncotarget, 2018 Aug 17; 9(56). PMID: 30112112    Free PMC article.
Refusing to TAP out: 16 new human TEIPPs identified.
Mathieu Gigoux, Jedd Wolchok.
J Exp Med, 2018 Aug 23; 215(9). PMID: 30131364    Free PMC article.
Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance.
Young-Jun Park, Da-Sol Kuen, Yeonseok Chung.
Exp Mol Med, 2018 Aug 24; 50(8). PMID: 30135516    Free PMC article.
Highly Cited. Review.
Epigenetic mechanisms of tumor resistance to immunotherapy.
Natalia Arenas-Ramirez, Dilara Sahin, Onur Boyman.
Cell Mol Life Sci, 2018 Aug 25; 75(22). PMID: 30140960
sLAG-3 in non-small-cell lung cancer patients' serum.
Yayi He, Yan Wang, +3 authors, Fred R Hirsch.
Onco Targets Ther, 2018 Aug 28; 11. PMID: 30147330    Free PMC article.
Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice.
Ying Wang, Lijing Su, +17 authors, Bruce Beutler.
Proc Natl Acad Sci U S A, 2018 Aug 29; 115(37). PMID: 30150374    Free PMC article.
Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
Qiaoyun Tan, Shuxia Liu, +2 authors, Yuankai Shi.
Thorac Cancer, 2018 Aug 29; 9(10). PMID: 30151899    Free PMC article.
Applications of tumor chip technology.
Stephanie J Hachey, Christopher C W Hughes.
Lab Chip, 2018 Aug 30; 18(19). PMID: 30156248    Free PMC article.
Aspects of Gut Microbiota and Immune System Interactions in Infectious Diseases, Immunopathology, and Cancer.
Veronica Lazar, Lia-Mara Ditu, +6 authors, Mariana Carmen Chifiriuc.
Front Immunol, 2018 Aug 31; 9. PMID: 30158926    Free PMC article.
Highly Cited. Review.
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
Jonathan A Trujillo, Randy F Sweis, Riyue Bao, Jason J Luke.
Cancer Immunol Res, 2018 Sep 06; 6(9). PMID: 30181337    Free PMC article.
Highly Cited.
Genetics and biology of prostate cancer.
Guocan Wang, Di Zhao, Denise J Spring, Ronald A DePinho.
Genes Dev, 2018 Sep 06; 32(17-18). PMID: 30181359    Free PMC article.
Has the melanoma information tsunami become a maelstrom?
John F Thompson, Alexander M Menzies.
Melanoma Manag, 2018 Sep 08; 4(4). PMID: 30190924    Free PMC article.
Genetic screen in myeloid cells identifies TNF-α autocrine secretion as a factor increasing MDSC suppressive activity via Nos2 up-regulation.
Matthias Schröder, Marit Krötschel, +6 authors, Lee Kim Swee.
Sci Rep, 2018 Sep 09; 8(1). PMID: 30194424    Free PMC article.
Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer.
Bryan E Strauss, Gissele Rolemberg Oliveira Silva, +4 authors, Samir Andrade Mendonça.
Clinics (Sao Paulo), 2018 Sep 13; 73(suppl 1). PMID: 30208166    Free PMC article.
Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
Guozhu Xie, Tan Cheng, +6 authors, Yawei Yuan.
J Immunother Cancer, 2018 Sep 14; 6(1). PMID: 30208943    Free PMC article.
Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic.
Johannes C Melms, Rohit Thummalapalli, +4 authors, Benjamin Izar.
J Immunother Cancer, 2018 Sep 14; 6(1). PMID: 30208947    Free PMC article.
Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
Fei Zhao, Kathy Evans, +6 authors, Brent A Hanks.
Cancer Immunol Res, 2018 Sep 14; 6(12). PMID: 30209062    Free PMC article.
New advances in immunotherapy for non-small cell lung cancer.
Haifeng Qin, Fang Wang, +4 authors, Hongjun Gao.
Am J Transl Res, 2018 Sep 14; 10(8). PMID: 30210667    Free PMC article.
[Molecular predictors in immune oncology].
W Weichert.
Pathologe, 2018 Sep 15; 39(6). PMID: 30215118
Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment.
Shohei Koyama, Izumi Nagatomo, Takashi Kijima, Atsushi Kumanogoh.
Oncotarget, 2018 Sep 18; 9(66). PMID: 30220963    Free PMC article.
Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies.
Shashi Gujar, Jonathan G Pol, Guido Kroemer.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221036    Free PMC article.
Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.
S Feola, C Capasso, +9 authors, V Cerullo.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221051    Free PMC article.
Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
Shan Feng, Xi Cheng, +10 authors, Xin Lu.
Proc Natl Acad Sci U S A, 2018 Sep 21; 115(40). PMID: 30232256    Free PMC article.
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.
Robin Maximilian Awad, Yannick De Vlaeminck, +2 authors, Karine Breckpot.
Front Immunol, 2018 Sep 21; 9. PMID: 30233579    Free PMC article.
Highly Cited. Review.
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.
K G Paulson, V Voillet, +20 authors, A G Chapuis.
Nat Commun, 2018 Sep 27; 9(1). PMID: 30250229    Free PMC article.
Highly Cited.
The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy.
Diana Klein.
Front Oncol, 2018 Sep 27; 8. PMID: 30250827    Free PMC article.
Highly Cited. Review.
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.
Veronica Huber, Viviana Vallacchi, +24 authors, Licia Rivoltini.
J Clin Invest, 2018 Sep 28; 128(12). PMID: 30260323    Free PMC article.
Highly Cited.
RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade.
Shanthi Ganesh, Xue Shui, +4 authors, Marc T Abrams.
Mol Ther, 2018 Oct 03; 26(11). PMID: 30274786    Free PMC article.
The intracellular signalosome of PD-L1 in cancer cells.
David Escors, María Gato-Cañas, +4 authors, Grazyna Kochan.
Signal Transduct Target Ther, 2018 Oct 03; 3. PMID: 30275987    Free PMC article.
Highly Cited. Review.
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
Akio Osa, Takeshi Uenami, +30 authors, Atsushi Kumanogoh.
JCI Insight, 2018 Oct 05; 3(19). PMID: 30282824    Free PMC article.
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
Jinfang Zhang, Fabin Dang, Junming Ren, Wenyi Wei.
Trends Biochem Sci, 2018 Oct 06; 43(12). PMID: 30287140    Free PMC article.
A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells.
Giulia Cesi, Demetra Philippidou, +10 authors, Stephanie Kreis.
Mol Cancer, 2018 Oct 07; 17(1). PMID: 30290811    Free PMC article.
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.
Jun Gong, Andrew Hendifar, +5 authors, Ravi Salgia.
Clin Transl Med, 2018 Oct 09; 7(1). PMID: 30294755    Free PMC article.
Let there be oxygen and T cells.
Paul R Walker.
J Clin Invest, 2018 Oct 16; 128(11). PMID: 30320602    Free PMC article.
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Jiawen Qian, Chen Wang, +7 authors, Yiwei Chu.
J Neuroinflammation, 2018 Oct 20; 15(1). PMID: 30333036    Free PMC article.
Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity.
Farideh Ordikhani, Mayuko Uehara, +12 authors, Reza Abdi.
JCI Insight, 2018 Oct 20; 3(20). PMID: 30333312    Free PMC article.
Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology.
Francesca Finotello, Federica Eduati.
Front Oncol, 2018 Oct 23; 8. PMID: 30345255    Free PMC article.
[Prognostic significance of immune cell infiltrates in tumor pathology].
D-C Wagner, W Roth.
Pathologe, 2018 Oct 24; 39(6). PMID: 30350175
Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells.
Zeiyad Alkarakooly, Qudes A Al-Anbaky, Krishnaswamy Kannan, Nawab Ali.
PLoS One, 2018 Oct 24; 13(10). PMID: 30352078    Free PMC article.
Defective transcription elongation in a subset of cancers confers immunotherapy resistance.
Vishnu Modur, Navneet Singh, +14 authors, Kakajan Komurov.
Nat Commun, 2018 Oct 26; 9(1). PMID: 30353012    Free PMC article.
The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.
Chloé Grasselly, Morgane Denis, +7 authors, Charles Dumontet.
Front Immunol, 2018 Oct 26; 9. PMID: 30356816    Free PMC article.
Improving Treatment for Myelodysplastic Syndromes Patients.
Julia Montoro, Aslihan Yerlikaya, Abdullah Ali, Azra Raza.
Curr Treat Options Oncol, 2018 Oct 27; 19(12). PMID: 30362079
Receptor-Targeted Glial Brain Tumor Therapies.
Puja Sharma, Waldemar Debinski.
Int J Mol Sci, 2018 Oct 28; 19(11). PMID: 30366424    Free PMC article.
Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy.
Gagandeep Brar, Tim F Greten, Zachary J Brown.
Therap Adv Gastroenterol, 2018 Nov 01; 11. PMID: 30377451    Free PMC article.
Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance.
Yong Liang, Haidong Tang, +12 authors, Yang-Xin Fu.
Nat Commun, 2018 Nov 06; 9(1). PMID: 30389912    Free PMC article.
Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Silvia C Formenti, Nils-Petter Rudqvist, +15 authors, Sandra Demaria.
Nat Med, 2018 Nov 07; 24(12). PMID: 30397353    Free PMC article.
Highly Cited.
Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2.
Zuqiang Liu, Yan Ge, +5 authors, David L Bartlett.
Nat Commun, 2018 Nov 10; 9(1). PMID: 30410056    Free PMC article.
Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer.
Masaru Katoh.
J Thorac Dis, 2018 Nov 13; 10(9). PMID: 30416762    Free PMC article.
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments.
Cristina Vajaitu, Carmen Cristina Draghici, +6 authors, Vlad Mihai Voiculescu.
J Immunol Res, 2018 Nov 13; 2018. PMID: 30417020    Free PMC article.
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials.
Christopher J LaRocca, Susanne G Warner.
Clin Transl Med, 2018 Nov 15; 7(1). PMID: 30426287    Free PMC article.
Highly Cited. Review.
Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer.
Donghai Xiong, Yian Wang, +3 authors, Ming You.
iScience, 2018 Nov 16; 9. PMID: 30439581    Free PMC article.
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Takayuki Kimura, Yu Kato, +10 authors, Kenichi Nomoto.
Cancer Sci, 2018 Nov 18; 109(12). PMID: 30447042    Free PMC article.
The Identification of Immunological Biomarkers in Kidney Cancers.
Antonio Lopez-Beltran, Vanessa Henriques, +7 authors, Rodolfo Montironi.
Front Oncol, 2018 Nov 20; 8. PMID: 30450335    Free PMC article.
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Francesco Sabbatino, Antonio Marra, +5 authors, Stefano Pepe.
J Immunother Cancer, 2018 Nov 22; 6(1). PMID: 30458852    Free PMC article.
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Zishuo Ian Hu, Matthew D Hellmann, +5 authors, Eileen M O'Reilly.
J Immunother Cancer, 2018 Nov 22; 6(1). PMID: 30458888    Free PMC article.
Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Jianqin Lu, Xiangsheng Liu, +6 authors, Andre E Nel.
ACS Nano, 2018 Nov 30; 12(11). PMID: 30481959    Free PMC article.
Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology.
Fatima Valdes-Mora, Kristina Handler, +4 authors, David Gallego-Ortega.
Front Immunol, 2018 Nov 30; 9. PMID: 30483257    Free PMC article.
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.
Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505714    Free PMC article.
Understanding tumor ecosystems by single-cell sequencing: promises and limitations.
Xianwen Ren, Boxi Kang, Zemin Zhang.
Genome Biol, 2018 Dec 05; 19(1). PMID: 30509292    Free PMC article.
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
Chien-Chun Steven Pai, John T Huang, +24 authors, Lawrence Fong.
Immunity, 2019 Feb 10; 50(2). PMID: 30737146    Free PMC article.
Highly Cited.
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Junfei Zhao, Andrew X Chen, +24 authors, Raul Rabadan.
Nat Med, 2019 Feb 12; 25(3). PMID: 30742119    Free PMC article.
Highly Cited.
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.
Umang Swami, Varun Monga, +4 authors, Mohammed Milhem.
Melanoma Res, 2019 Mar 05; 29(6). PMID: 30829928    Free PMC article.
Adrenergic Receptor Signaling Regulates the Response of Tumors to Ionizing Radiation.
Cameron R MacDonald, Mark J Bucsek, +10 authors, Elizabeth A Repasky.
Radiat Res, 2019 Apr 26; 191(6). PMID: 31021732    Free PMC article.
Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
Jason J Luke.
Oncologist, 2019 May 09; 24(11). PMID: 31064886    Free PMC article.
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Dongkui Song, Thomas Powles, +3 authors, Yong-Jie Lu.
J Pathol, 2019 May 19; 249(2). PMID: 31102277    Free PMC article.
Application of PD-1 Blockade in Cancer Immunotherapy.
Xiaomo Wu, Zhongkai Gu, +4 authors, Xiaolong Liu.
Comput Struct Biotechnol J, 2019 Jun 18; 17. PMID: 31205619    Free PMC article.
Highly Cited. Review.
Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation.
Alex M Jaeger, Lauren Stopfer, +9 authors, Luke Whitesell.
Clin Cancer Res, 2019 Jun 20; 25(21). PMID: 31213460    Free PMC article.
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Hannah Yang, Won Suk Lee, +7 authors, Chan Kim.
J Clin Invest, 2019 Jul 26; 129(10). PMID: 31343989    Free PMC article.
Novel Delivery Systems for Checkpoint Inhibitors.
Purushottam Lamichhane, Rahul Deshmukh, +8 authors, Narottam Lamichhane.
Medicines (Basel), 2019 Aug 03; 6(3). PMID: 31373327    Free PMC article.
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity.
Mario Martínez Soldevilla, Helena Villanueva, +10 authors, Fernando Pastor.
Mol Ther, 2019 Aug 14; 27(11). PMID: 31405808    Free PMC article.
T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.
Stacey L Doran, Sanja Stevanović, +9 authors, Christian S Hinrichs.
J Clin Oncol, 2019 Aug 14; 37(30). PMID: 31408414    Free PMC article.
STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.
Rana Falahat, Patricio Perez-Villarroel, +4 authors, James J Mulé.
Cancer Immunol Res, 2019 Aug 30; 7(11). PMID: 31462408    Free PMC article.
Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine.
Hiro Sato, Penny A Jeggo, Atsushi Shibata.
Cancer Sci, 2019 Sep 13; 110(11). PMID: 31513320    Free PMC article.
Role of CXCR3 signaling in response to anti-PD-1 therapy.
Xiao Han, Ying Wang, +12 authors, Yanhong Gu.
EBioMedicine, 2019 Sep 16; 48. PMID: 31521609    Free PMC article.
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.
Yochai Wolf, Osnat Bartok, +26 authors, Yardena Samuels.
Cell, 2019 Sep 17; 179(1). PMID: 31522890    Free PMC article.
Highly Cited.
Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies.
Emily Hays, Benjamin Bonavida.
Antioxidants (Basel), 2019 Sep 20; 8(9). PMID: 31533363    Free PMC article.
Polydopamine-Based "Four-in-One" Versatile Nanoplatforms for Targeted Dual Chemo and Photothermal Synergistic Cancer Therapy.
Gan Liu, Nansha Gao, +6 authors, Wenbin Deng.
Pharmaceutics, 2019 Oct 05; 11(10). PMID: 31581532    Free PMC article.
Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.
Valli De Re, Laura Caggiari, +2 authors, Maurizio Mascarin.
J Clin Med, 2019 Oct 05; 8(10). PMID: 31581738    Free PMC article.
Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity.
Guangchuan Wang, Ryan D Chow, +12 authors, Sidi Chen.
Nat Immunol, 2019 Oct 16; 20(11). PMID: 31611701    Free PMC article.
NK Cell-Fc Receptors Advance Tumor Immunotherapy.
Emilio Sanseviero.
J Clin Med, 2019 Oct 17; 8(10). PMID: 31614774    Free PMC article.
Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.
Colin Sheehan, Crislyn D'Souza-Schorey.
J Cell Sci, 2019 Oct 17; 132(20). PMID: 31615844    Free PMC article.
WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Xin Li, Yanwei Xiang, +3 authors, Xisong Ke.
Front Immunol, 2019 Oct 17; 10. PMID: 31616443    Free PMC article.
A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning.
Maurizio Polano, Marco Chierici, +6 authors, Giuseppe Toffoli.
Cancers (Basel), 2019 Oct 18; 11(10). PMID: 31618839    Free PMC article.
Monalizumab: inhibiting the novel immune checkpoint NKG2A.
Thorbald van Hall, Pascale André, +6 authors, Eric Vivier.
J Immunother Cancer, 2019 Oct 19; 7(1). PMID: 31623687    Free PMC article.
γδ T cells in cancer: a small population of lymphocytes with big implications.
Mathilde Raverdeau, Stephen P Cunningham, Cathal Harmon, Lydia Lynch.
Clin Transl Immunology, 2019 Oct 19; 8(10). PMID: 31624593    Free PMC article.
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.
Muhammad Z Afzal, Konstantin Dragnev, Tayyaba Sarwar, Keisuke Shirai.
Lung Cancer Manag, 2019 Oct 28; 8(2). PMID: 31645894    Free PMC article.
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome.
María Del Mar Noblejas-López, Cristina Nieto-Jiménez, +8 authors, Alberto Ocana.
Oncoimmunology, 2019 Oct 28; 8(10). PMID: 31646075    Free PMC article.
A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice.
Sarah Lévesque, Julie Le Naour, +12 authors, Jonathan G Pol.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646107    Free PMC article.
Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39.
Said A Goueli, Kevin Hsiao.
PLoS One, 2019 Oct 28; 14(10). PMID: 31652269    Free PMC article.
Are we facing a cure in lung cancer?-KEYNOTE-001 insights.
Aharon Y Cohen, Waleed Kian, +3 authors, Yulia Dudnik.
Ann Transl Med, 2019 Oct 28; 7(Suppl 6). PMID: 31656794    Free PMC article.
Immunomodulatory aspects in the progression and treatment of oral malignancy.
Nobuo Kondoh, Masako Mizuno-Kamiya, +5 authors, Shinichiro Sumitomo.
Jpn Dent Sci Rev, 2019 Oct 30; 55(1). PMID: 31660091    Free PMC article.
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
Crescenzo D'Alterio, Maria Buoncervello, +16 authors, Stefania Scala.
J Exp Clin Cancer Res, 2019 Oct 30; 38(1). PMID: 31661001    Free PMC article.
Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma.
Luigi Fattore, Ciro Francesco Ruggiero, +2 authors, Gennaro Ciliberto.
Cell Death Dis, 2019 Nov 02; 10(11). PMID: 31672982    Free PMC article.
Small molecules as theranostic agents in cancer immunology.
Jindian Li, Juno Van Valkenburgh, +3 authors, Kai Chen.
Theranostics, 2019 Nov 07; 9(25). PMID: 31695804    Free PMC article.
Towards early monitoring of chemotherapy-induced drug resistance based on single cell metabolomics: Combining single-probe mass spectrometry with machine learning.
Renmeng Liu, Mei Sun, +2 authors, Zhibo Yang.
Anal Chim Acta, 2019 Nov 12; 1092. PMID: 31708031    Free PMC article.
Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Peng Zhang, Jason Miska, +11 authors, Maciej S Lesniak.
Proc Natl Acad Sci U S A, 2019 Nov 13; 116(47). PMID: 31712430    Free PMC article.
Oxidized low density lipoprotein receptor 1 promotes lung metastases of osteosarcomas through regulating the epithelial-mesenchymal transition.
Long Jiang, Shanshan Jiang, +4 authors, Qingquan Luo.
J Transl Med, 2019 Nov 14; 17(1). PMID: 31718700    Free PMC article.
Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients.
Xuan-Zhang Huang, Peng Gao, +5 authors, Zhen-Ning Wang.
Oncoimmunology, 2019 Nov 20; 8(12). PMID: 31741763    Free PMC article.
Bone marrow expands the repertoire of functional T cells targeting tumor-associated antigens in patients with resectable non-small-cell lung cancer.
Seyer Safi, Yoshikane Yamauchi, +11 authors, Philipp Beckhove.
Oncoimmunology, 2019 Nov 20; 8(12). PMID: 31741774    Free PMC article.
Tissue-specific tumor microenvironments influence responses to immunotherapies.
Amanda J Oliver, Ashleigh S Davey, +9 authors, Clare Y Slaney.
Clin Transl Immunology, 2019 Nov 27; 8(11). PMID: 31768254    Free PMC article.
Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy.
Liangrong Shi, Junjun Wang, +13 authors, Weihua Liao.
Nat Commun, 2019 Nov 30; 10(1). PMID: 31780645    Free PMC article.
Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor.
Qingzhi Jiang, Chi Zhang, +5 authors, Chunmeng Shi.
Front Oncol, 2019 Nov 30; 9. PMID: 31781498    Free PMC article.
Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance.
Dayana B Rivadeneira, Kristin DePeaux, +9 authors, Greg M Delgoffe.
Immunity, 2019 Sep 01; 51(3). PMID: 31471106    Free PMC article.
The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality.
Chaofan Li, Bibo Zhu, +18 authors, Jie Sun.
Immunity, 2019 Sep 19; 51(3). PMID: 31533057    Free PMC article.
Highly Cited.
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.
Grace Wakabayashi, Yu-Ching Lee, +3 authors, Yun Yen.
J Biomed Sci, 2019 Dec 06; 26(1). PMID: 31801525    Free PMC article.
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
Ezra E W Cohen, Michael J Pishvaian, +10 authors, Steven F Powell.
J Immunother Cancer, 2019 Dec 06; 7(1). PMID: 31801624    Free PMC article.
The Role of Long Non-coding RNAs in Immunotherapy Resistance.
Yuwen Zhou, Yajuan Zhu, Yao Xie, Xuelei Ma.
Front Oncol, 2019 Dec 19; 9. PMID: 31850199    Free PMC article.
Genetic instability as a driver for immune surveillance.
Guim Aguadé-Gorgorió, Ricard Solé.
J Immunother Cancer, 2019 Dec 13; 7(1). PMID: 31829285    Free PMC article.
Biomarker for personalized immunotherapy.
Si-Yang Liu, Yi-Long Wu.
Transl Lung Cancer Res, 2019 Dec 21; 8(Suppl 3). PMID: 31857954    Free PMC article.
Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy.
Li Li, Yubo Wang, +5 authors, Yong He.
Cancer Med, 2019 Nov 07; 8(18). PMID: 31692284    Free PMC article.
Discovery of Small Molecules for the Reversal of T Cell Exhaustion.
Brett S Marro, Jaroslav Zak, +3 authors, Michael B A Oldstone.
Cell Rep, 2019 Dec 05; 29(10). PMID: 31801090    Free PMC article.
Cancer stem cells-driven tumor growth and immune escape: the Janus face of neurotrophins.
Viviana Triaca, Valentina Carito, +6 authors, Paola Tirassa.
Aging (Albany NY), 2019 Dec 10; 11(23). PMID: 31812953    Free PMC article.
TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Alisha Holtzhausen, William Harris, +9 authors, H Shelton Earp.
Cancer Immunol Res, 2019 Aug 28; 7(10). PMID: 31451482    Free PMC article.
Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.
Kohei Fujita, Yuki Yamamoto, +5 authors, Tadashi Mio.
Thorac Cancer, 2019 Nov 09; 11(1). PMID: 31701630    Free PMC article.
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Anna Pavlick, Ana B Blazquez, +12 authors, Nina Bhardwaj.
Cancer Immunol Res, 2019 Nov 09; 8(1). PMID: 31699709    Free PMC article.
CXCR3: Here to stay to enhance cancer immunotherapy?
Meri Rogava, Benjamin Izar.
EBioMedicine, 2019 Nov 07; 49. PMID: 31690542    Free PMC article.
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Lawrence Fong, Andrew Hotson, +30 authors, Richard A Miller.
Cancer Discov, 2019 Nov 17; 10(1). PMID: 31732494    Free PMC article.
Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer.
Cindy Mendes, Jacinta Serpa.
Antioxidants (Basel), 2019 Dec 05; 8(12). PMID: 31795465    Free PMC article.
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.
Javier Pérez-Pena, Janos Tibor Fekete, +9 authors, Alberto Ocana.
Front Immunol, 2020 Jan 11; 10. PMID: 31921107    Free PMC article.
The Intriguing History of Cancer Immunotherapy.
Paula Dobosz, Tomasz Dzieciątkowski.
Front Immunol, 2020 Jan 11; 10. PMID: 31921205    Free PMC article.
An assessment of Oxford Nanopore sequencing for human gut metagenome profiling: A pilot study of head and neck cancer patients.
Thidathip Wongsurawat, Mayumi Nakagawa, +7 authors, Intawat Nookaew.
J Microbiol Methods, 2019 Oct 19; 166. PMID: 31626891    Free PMC article.
Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs.
Patrizia Leone, Alessio Buonavoglia, +5 authors, Vito Racanelli.
J Clin Med, 2019 Nov 24; 8(12). PMID: 31757094    Free PMC article.
Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.
Reham Ajina, David J Zahavi, Yong-Wei Zhang, Louis M Weiner.
Semin Cancer Biol, 2019 Dec 24; 65. PMID: 31866479    Free PMC article.
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Abhishek S Kashyap, Martina Schmittnaegel, +18 authors, Alfred Zippelius.
Proc Natl Acad Sci U S A, 2020 Jan 01; 117(1). PMID: 31889004    Free PMC article.
Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Bo Wang, Yingke Zhou, +3 authors, Haojie Huang.
Theranostics, 2020 Jan 16; 10(3). PMID: 31938049    Free PMC article.
Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance.
Jose L Orgaz, Eva Crosas-Molist, +16 authors, Victoria Sanz-Moreno.
Cancer Cell, 2020 Jan 15; 37(1). PMID: 31935375    Free PMC article.
Current Status of Immunotherapy for Lung Cancer and Future Perspectives.
Ho Cheol Kim, Chang Min Choi.
Tuberc Respir Dis (Seoul), 2020 Jan 07; 83(1). PMID: 31905428    Free PMC article.
Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer.
Ana Paula Dinis Ano Bom, Patrícia Cristina da Costa Neves, +2 authors, Sotiris Missailidis.
Pharmaceutics, 2020 Jan 01; 11(12). PMID: 31888119    Free PMC article.
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Ilaria Alborelli, Katharina Leonards, +12 authors, Philip Jermann.
J Pathol, 2019 Sep 01; 250(1). PMID: 31471895    Free PMC article.
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors.
Nicholas Gravbrot, Kacy Gilbert-Gard, +4 authors, Srinath Sundararajan.
Antibodies (Basel), 2019 Oct 24; 8(4). PMID: 31640266    Free PMC article.
HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors.
Kwon-Ho Song, Se Jin Oh, +13 authors, Tae Woo Kim.
Nat Commun, 2020 Jan 30; 11(1). PMID: 31992715    Free PMC article.
The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment.
Bo Ma, Alan Wells, Amanda M Clark.
Semin Cancer Biol, 2019 Aug 04; 60. PMID: 31376430    Free PMC article.
Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells.
Xiaoxu Ge, Yamei Zhao, +2 authors, Lifeng Sun.
Onco Targets Ther, 2020 Jan 31; 12. PMID: 31997881    Free PMC article.
Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors.
Ana Alcaraz-Sanabria, Mariona Baliu-Piqué, +9 authors, Alberto Ocana.
Front Oncol, 2020 Jan 31; 9. PMID: 31998644    Free PMC article.
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
Isaure Vanmeerbeek, Jenny Sprooten, +8 authors, Abhishek D Garg.
Oncoimmunology, 2020 Feb 01; 9(1). PMID: 32002302    Free PMC article.
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells.
Jason B Williams, Shuyin Li, +4 authors, Thomas F Gajewski.
Nat Commun, 2020 Feb 01; 11(1). PMID: 32001684    Free PMC article.
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
Daixi Ren, Yuze Hua, +17 authors, Wei Xiong.
Mol Cancer, 2020 Feb 01; 19(1). PMID: 32000802    Free PMC article.
The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies".
Thomas Strub, Robert Ballotti, Corine Bertolotto.
Theranostics, 2020 Feb 12; 10(4). PMID: 32042336    Free PMC article.
HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Sayuri Miyauchi, P Dominick Sanders, +7 authors, Andrew B Sharabi.
Cancer Res, 2019 Dec 19; 80(4). PMID: 31848196    Free PMC article.
A Targeted Quantitative Proteomic Method Revealed a Substantial Reprogramming of Kinome during Melanoma Metastasis.
Weili Miao, Lin Li, +4 authors, Yinsheng Wang.
Sci Rep, 2020 Feb 14; 10(1). PMID: 32051510    Free PMC article.
Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy.
Zecong Xiao, Zhenwei Su, +3 authors, Xintao Shuai.
Sci Adv, 2020 Feb 23; 6(6). PMID: 32076650    Free PMC article.
Recent advances in the clinical development of immune checkpoint blockade therapy.
Atefeh Ghahremanloo, Arash Soltani, Seyed Mohamad Sadegh Modaresi, Seyed Isaac Hashemy.
Cell Oncol (Dordr), 2019 Jun 16; 42(5). PMID: 31201647
Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer.
Sean J Judge, Mio Yanagisawa, +11 authors, Robert J Canter.
PLoS One, 2020 Feb 23; 15(2). PMID: 32084139    Free PMC article.
Effect of pembrolizumab on CD4+ CD25+ , CD4+ LAP+ and CD4+ TIM-3+ T cell subsets.
S M Toor, V Sasidharan Nair, G Pfister, E Elkord.
Clin Exp Immunol, 2019 Jan 30; 196(3). PMID: 30693485    Free PMC article.
The Immune Subtypes and Landscape of Squamous Cell Carcinoma.
Bailiang Li, Yi Cui, +2 authors, Ruijiang Li.
Clin Cancer Res, 2019 Mar 06; 25(12). PMID: 30833271    Free PMC article.
Structure and Optimization of Checkpoint Inhibitors.
Sarah L Picardo, Jeffrey Doi, Aaron R Hansen.
Cancers (Basel), 2019 Dec 28; 12(1). PMID: 31877721    Free PMC article.
Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities.
Véronique Debien, Jonathan Thouvenin, +4 authors, Gabriel G Malouf.
Cancers (Basel), 2020 Jan 08; 12(1). PMID: 31906050    Free PMC article.
Identification of altered biological processes in heterogeneous RNA-sequencing data by discretization of expression profiles.
Andrea Lauria, Serena Peirone, +5 authors, Matteo Cereda.
Nucleic Acids Res, 2020 Jan 01; 48(4). PMID: 31889184    Free PMC article.
TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy.
Adam S Dayoub, Rolf A Brekken.
Cell Commun Signal, 2020 Feb 24; 18(1). PMID: 32087708    Free PMC article.
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
Qingyang Xiao, André Nobre, +5 authors, Isabel Barragán.
J Clin Med, 2020 Jan 24; 9(1). PMID: 31968651    Free PMC article.
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.
Sara Saab, Hussein Zalzale, +3 authors, Humam Kadara.
Front Immunol, 2020 Mar 03; 11. PMID: 32117295    Free PMC article.
Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens.
Yong Luo, Chaolong Lin, +13 authors, Ningshao Xia.
Oncoimmunology, 2020 Mar 03; 9(1). PMID: 32117591    Free PMC article.
My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
Alexander Levitzki, Shoshana Klein.
Proc Natl Acad Sci U S A, 2019 May 12; 116(24). PMID: 31076554    Free PMC article.
Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.
Yasuo Takashima, Atsushi Kawaguchi, +12 authors, Ryuya Yamanaka.
Sci Rep, 2019 Jul 12; 9(1). PMID: 31292525    Free PMC article.
Acquired resistance to cancer immunotherapy.
Arianna Draghi, Christopher Aled Chamberlain, Andrew Furness, Marco Donia.
Semin Immunopathol, 2018 Jul 04; 41(1). PMID: 29968044
Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.
María E Rodríguez-Ruiz, Claire Vanpouille-Box, +2 authors, Sandra Demaria.
Trends Immunol, 2018 Jul 14; 39(8). PMID: 30001871    Free PMC article.
Highly Cited. Review.
Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications.
Tanner Smida, Tullia C Bruno, Laura P Stabile.
Front Oncol, 2020 Mar 07; 10. PMID: 32133288    Free PMC article.
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
Jessica L F Teh, Andrew E Aplin.
Clin Cancer Res, 2018 Oct 06; 25(3). PMID: 30287548    Free PMC article.
Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
Viswanath Gunda, Benjamin Gigliotti, +7 authors, Sareh Parangi.
Br J Cancer, 2018 Oct 18; 119(10). PMID: 30327563    Free PMC article.
Comparing the effects of different cell death programs in tumor progression and immunotherapy.
Michelle N Messmer, Annelise G Snyder, Andrew Oberst.
Cell Death Differ, 2018 Oct 21; 26(1). PMID: 30341424    Free PMC article.
The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match.
Vivek Subbiah, Razelle Kurzrock.
Oncologist, 2018 Oct 26; 24(1). PMID: 30352943    Free PMC article.
The Interferon-Gamma Paradox in Cancer.
M Raza Zaidi.
J Interferon Cytokine Res, 2018 Nov 06; 39(1). PMID: 30388040    Free PMC article.
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Livnat Jerby-Arnon, Parin Shah, +49 authors, Aviv Regev.
Cell, 2018 Nov 06; 175(4). PMID: 30388455    Free PMC article.
Highly Cited.
Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function.
Eric Shifrut, Julia Carnevale, +7 authors, Alexander Marson.
Cell, 2018 Nov 20; 175(7). PMID: 30449619    Free PMC article.
Highly Cited.
Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
Dhiraj Kumar, Ala Lisok, +15 authors, Sridhar Nimmagadda.
J Clin Invest, 2018 Nov 21; 129(2). PMID: 30457978    Free PMC article.
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
Nadine van Montfoort, Linda Borst, +13 authors, Thorbald van Hall.
Cell, 2018 Dec 07; 175(7). PMID: 30503208    Free PMC article.
Highly Cited.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
Pascale André, Caroline Denis, +27 authors, Eric Vivier.
Cell, 2018 Dec 07; 175(7). PMID: 30503213    Free PMC article.
Highly Cited. Review.
A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.
Sanja Stevanović, Sarah R Helman, +10 authors, Christian S Hinrichs.
Clin Cancer Res, 2018 Dec 07; 25(5). PMID: 30518633    Free PMC article.
Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
Shannon Grabosch, Mirna Bulatovic, +11 authors, Anda M Vlad.
Oncogene, 2018 Dec 07; 38(13). PMID: 30518877    Free PMC article.
Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
Gang Shi, Qianmei Yang, +21 authors, Hongxin Deng.
Mol Ther, 2018 Dec 12; 27(1). PMID: 30527756    Free PMC article.
Unraveling the Cellular Mechanism of Assembling Cholesterols for Selective Cancer Cell Death.
Huaimin Wang, Zhaoqianqi Feng, +7 authors, Bing Xu.
Mol Cancer Res, 2018 Dec 16; 17(4). PMID: 30552234    Free PMC article.
The Yin and Yang of Myeloid Derived Suppressor Cells.
Snehil Budhwar, Priyanka Verma, +2 authors, Kiran Singh.
Front Immunol, 2018 Dec 18; 9. PMID: 30555467    Free PMC article.
DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers.
Juan Ruiz-Bañobre, Ajay Goel.
Gastroenterology, 2018 Dec 24; 156(4). PMID: 30578781    Free PMC article.
A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor.
Mark D M Leiserson, Vasilis Syrgkanis, +9 authors, Lester Mackey.
PLoS One, 2019 Jan 01; 13(12). PMID: 30596661    Free PMC article.
The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity.
Shannon M White, Shigekazu Murakami, Chunling Yi.
Oncogene, 2019 Jan 09; 38(16). PMID: 30617303    Free PMC article.
Highly Cited. Review.
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Zong Sheng Guo, Binfeng Lu, +8 authors, David L Bartlett.
J Immunother Cancer, 2019 Jan 11; 7(1). PMID: 30626434    Free PMC article.
Highly Cited. Review.
Translation control of the immune checkpoint in cancer and its therapeutic targeting.
Yichen Xu, Mauro Poggio, +18 authors, Davide Ruggero.
Nat Med, 2019 Jan 16; 25(2). PMID: 30643286    Free PMC article.
Highly Cited.
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Vinod P Balachandran, Gregory L Beatty, Stephanie K Dougan.
Gastroenterology, 2019 Jan 21; 156(7). PMID: 30660727    Free PMC article.
Highly Cited. Review.
A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
Lucia D'Amico, Ulrike Menzel, +16 authors, Alfred Zippelius.
J Immunother Cancer, 2019 Jan 23; 7(1). PMID: 30665463    Free PMC article.
Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells.
Christine E Nelson, Lauren J Mills, +6 authors, Vaiva Vezys.
Proc Natl Acad Sci U S A, 2019 Jan 27; 116(7). PMID: 30679280    Free PMC article.
Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy.
Pamela C Rosato, Sathi Wijeyesinghe, +9 authors, David Masopust.
Nat Commun, 2019 Feb 06; 10(1). PMID: 30718505    Free PMC article.
Highly Cited.
Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.
Nathan Simon, Antonella Antignani, +3 authors, David FitzGerald.
JCI Insight, 2019 Feb 06; 4(5). PMID: 30720466    Free PMC article.
Immunotherapy for skin cancer.
Kelly G Paulson, Miranda C Lahman, Aude G Chapuis, Isaac Brownell.
Int Immunol, 2019 Feb 13; 31(7). PMID: 30753483    Free PMC article.
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Triparna Sen, B Leticia Rodriguez, +16 authors, Lauren A Byers.
Cancer Discov, 2019 Feb 20; 9(5). PMID: 30777870    Free PMC article.
Highly Cited.
Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo.
Adan Codina, Paul A Renauer, +16 authors, Sidi Chen.
Cell Syst, 2019 Feb 25; 8(2). PMID: 30797773    Free PMC article.
Genomic correlates of response to immune checkpoint blockade.
Tanya E Keenan, Kelly P Burke, Eliezer M Van Allen.
Nat Med, 2019 Mar 08; 25(3). PMID: 30842677    Free PMC article.
Highly Cited. Review.
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Marie-Eve Beaulieu, Toni Jauset, +21 authors, Laura Soucek.
Sci Transl Med, 2019 Mar 22; 11(484). PMID: 30894502    Free PMC article.
Highly Cited.
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Karin M Knudson, Kristin C Hicks, +2 authors, Sofia R Gameiro.
J Immunother Cancer, 2019 Mar 23; 7(1). PMID: 30898149    Free PMC article.
KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
Wenting Liao, Michael J Overman, +24 authors, Ronald A DePinho.
Cancer Cell, 2019 Mar 25; 35(4). PMID: 30905761    Free PMC article.
Highly Cited.
Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance.
Jinqi Liu, Joshua Curtin, +19 authors, Luisa Salter-Cid.
PLoS One, 2019 Mar 27; 14(3). PMID: 30913212    Free PMC article.
Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer.
Jin Xu, Yun Qiu.
Asian J Androl, 2019 Mar 30; 21(3). PMID: 30924449    Free PMC article.
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Mauro Poggio, Tianyi Hu, +8 authors, Robert Blelloch.
Cell, 2019 Apr 06; 177(2). PMID: 30951669    Free PMC article.
Highly Cited.
Downregulation of CD73 associates with T cell exhaustion in AML patients.
Yaxian Kong, Bei Jia, +8 authors, Hong Zheng.
J Hematol Oncol, 2019 Apr 25; 12(1). PMID: 31014364    Free PMC article.
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities.
Suhas Vasaikar, Chen Huang, +30 authors, Clinical Proteomic Tumor Analysis Consortium.
Cell, 2019 Apr 30; 177(4). PMID: 31031003    Free PMC article.
Highly Cited.
A network approach to developing immuno-oncology combinations in Canada.
V Higenell, R Fajzel, +11 authors, S Verma.
Curr Oncol, 2019 May 03; 26(2). PMID: 31043804    Free PMC article.
Hippo Pathway in Mammalian Adaptive Immune System.
Takayoshi Yamauchi, Toshiro Moroishi.
Cells, 2019 May 06; 8(5). PMID: 31052239    Free PMC article.
The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.
Dan A Erkes, Conroy O Field, +7 authors, Andrew E Aplin.
Pigment Cell Melanoma Res, 2019 May 08; 32(5). PMID: 31063649    Free PMC article.
Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells.
M Feng, J Q Jin, +11 authors, D Zhu.
Sci Adv, 2019 May 16; 5(5). PMID: 31086813    Free PMC article.
Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development.
Gabriel Helmlinger, Victor Sokolov, +11 authors, Robert C Penland.
CPT Pharmacometrics Syst Pharmacol, 2019 May 16; 8(6). PMID: 31087533    Free PMC article.
The microbiota and microbiome in pancreatic cancer: more influential than expected.
Miao-Yan Wei, Si Shi, +7 authors, Xian-Jun Yu.
Mol Cancer, 2019 May 22; 18(1). PMID: 31109338    Free PMC article.
Highly Cited. Review.
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Siwen Hu-Lieskovan, Aaron Lisberg, +16 authors, Edward B Garon.
Clin Cancer Res, 2019 May 23; 25(16). PMID: 31113840    Free PMC article.
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Melissa L Johnson, Fadi Braiteh, +7 authors, Siwen Hu-Lieskovan.
JAMA Oncol, 2019 May 31; 5(7). PMID: 31145415    Free PMC article.
A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma.
Wenna Guo, Liucun Zhu, +3 authors, Jian-Qun Chen.
Elife, 2019 Jun 07; 8. PMID: 31169496    Free PMC article.
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy.
Mónica Pascual-García, Ester Bonfill-Teixidor, +21 authors, Joan Seoane.
Nat Commun, 2019 Jun 13; 10(1). PMID: 31186412    Free PMC article.
Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology.
Hansaim Lim, Di He, +3 authors, Lei Xie.
PLoS Comput Biol, 2019 Jun 18; 15(6). PMID: 31206508    Free PMC article.
Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.
Anna Morena D'Alise, Guido Leoni, +17 authors, Elisa Scarselli.
Nat Commun, 2019 Jun 21; 10(1). PMID: 31217437    Free PMC article.
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.
Seungwon Yang, Jiangbo Wei, +8 authors, Yu-Ying He.
Nat Commun, 2019 Jun 27; 10(1). PMID: 31239444    Free PMC article.
Highly Cited.
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
Li-Chuan Chan, Chia-Wei Li, +26 authors, Mien-Chie Hung.
J Clin Invest, 2019 Jul 16; 129(8). PMID: 31305264    Free PMC article.
Highly Cited.
Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation.
Shabnam Shalapour, Michael Karin.
Immunity, 2019 Jul 18; 51(1). PMID: 31315033    Free PMC article.
Highly Cited. Review.
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.
Mengshi Li, Dijie Liu, +9 authors, Michael K Schultz.
Mol Pharm, 2019 Jul 19; 16(9). PMID: 31318566    Free PMC article.
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
Xiaoguang Li, Zhida Liu, +8 authors, Yang-Xin Fu.
Nat Commun, 2019 Jul 22; 10(1). PMID: 31324798    Free PMC article.
Macrophage-Mediated Subversion of Anti-Tumour Immunity.
Valeria Quaranta, Michael C Schmid.
Cells, 2019 Jul 25; 8(7). PMID: 31331034    Free PMC article.
Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ.
Chang Liu, Maria Chikina, +13 authors, Dario A A Vignali.
Immunity, 2019 Jul 28; 51(2). PMID: 31350177    Free PMC article.
Highly Cited.
Cancer cell reprogramming: a promising therapy converting malignancy to benignity.
Lanqi Gong, Qian Yan, +3 authors, Xinyuan Guan.
Cancer Commun (Lond), 2019 Aug 30; 39(1). PMID: 31464654    Free PMC article.
An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Hiroki Tsukamoto, Kanae Kubota, +5 authors, Yoshihisa Tomioka.
Immunology, 2019 Sep 14; 158(2). PMID: 31515801    Free PMC article.
Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers.
Yves Lecarpentier, Olivier Schussler, Jean-Louis Hébert, Alexandre Vallée.
Front Oncol, 2019 Dec 06; 9. PMID: 31803621    Free PMC article.
Cancer Nano-Immunotherapy from the Injection to the Target: The Role of Protein Corona.
Idoia Mikelez-Alonso, Antonio Aires, Aitziber L Cortajarena.
Int J Mol Sci, 2020 Jan 18; 21(2). PMID: 31947622    Free PMC article.
miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
Yasuo Takashima, Atsushi Kawaguchi, +5 authors, Ryuya Yamanaka.
PLoS One, 2020 Feb 27; 15(2). PMID: 32101576    Free PMC article.
Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer.
Alejandro Herreros-Pomares, Juan Diego de-Maya-Girones, +16 authors, Carlos Camps.
Cell Death Dis, 2019 Sep 12; 10(9). PMID: 31506430    Free PMC article.
High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer.
Xiaobo Bo, Jie Wang, +12 authors, Houbao Liu.
Cancer Sci, 2020 Jan 12; 111(3). PMID: 31925976    Free PMC article.
Synthetic lethal therapy based on targeting the vulnerability of SWI/SNF chromatin remodeling complex-deficient cancers.
Mariko Sasaki, Hideaki Ogiwara.
Cancer Sci, 2020 Jan 20; 111(3). PMID: 31955490    Free PMC article.
Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma.
Jing-Yuan Cao, Qing Guo, +8 authors, Guang-Yu Li.
Aging (Albany NY), 2020 Feb 01; 12(2). PMID: 32003759    Free PMC article.
Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Aviad Ben-Shmuel, Guy Biber, Mira Barda-Saad.
Front Immunol, 2020 Mar 11; 11. PMID: 32153582    Free PMC article.
Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis.
Se Jin Oh, Jaeyoon Lee, +5 authors, Tae Woo Kim.
Immune Netw, 2020 Mar 12; 20(1). PMID: 32158595    Free PMC article.
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy.
Kyung Hwan Kim, Chang Gon Kim, Eui-Cheol Shin.
Immune Netw, 2020 Mar 12; 20(1). PMID: 32158596    Free PMC article.
Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Shyambabu Chaurasiya, Annie Yang, +8 authors, Yuman Fong.
Oncoimmunology, 2020 Mar 12; 9(1). PMID: 32158622    Free PMC article.
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.
Guan Wang, Xi Kang, +5 authors, Si-Yi Chen.
Nat Commun, 2020 Mar 15; 11(1). PMID: 32170083    Free PMC article.
Treating non-responders: pitfalls and implications for cancer immunotherapy trial design.
Zhenzhen Xu, Yongsoek Park, Ke Liu, Bin Zhu.
J Hematol Oncol, 2020 Mar 17; 13(1). PMID: 32171307    Free PMC article.
Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas.
Alexandros Bokas, Pavlos Papakotoulas, +3 authors, Michalis V Karamouzis.
Cancers (Basel), 2020 Feb 20; 12(2). PMID: 32069809    Free PMC article.
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
Victor C Kok.
Front Oncol, 2020 Mar 19; 10. PMID: 32185135    Free PMC article.
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
Anna Minchom, Wei Yuan, +19 authors, Juanita Lopez.
J Immunother Cancer, 2020 Mar 15; 8(1). PMID: 32169873    Free PMC article.
The HIPPO pathway in gynecological malignancies.
Dongying Wang, Jiaxing He, +2 authors, Tianmin Xu.
Am J Cancer Res, 2020 Mar 21; 10(2). PMID: 32195031    Free PMC article.
Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination.
Zhiwu Tan, Mei Sum Chiu, +4 authors, Zhiwei Chen.
Mol Ther Oncolytics, 2020 Mar 21; 16. PMID: 32195318    Free PMC article.
Determinants of Resistance to Checkpoint Inhibitors.
Linda Tran, Dan Theodorescu.
Int J Mol Sci, 2020 Mar 01; 21(5). PMID: 32111080    Free PMC article.
Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors.
Adrian Bubie, Edgar Gonzalez-Kozlova, +2 authors, Bojan Losic.
Sci Rep, 2020 Mar 21; 10(1). PMID: 32193450    Free PMC article.
The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.
Paolo A Ascierto, Lisa H Butterfield, +8 authors, Igor Puzanov.
J Immunother Cancer, 2019 Aug 17; 7(1). PMID: 31416487    Free PMC article.
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Lorenzo Galluzzi, Ilio Vitale, +51 authors, Francesco M Marincola.
J Immunother Cancer, 2020 Mar 27; 8(1). PMID: 32209603    Free PMC article.
Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Mehdi R Pirozyan, Helen M McGuire, +9 authors, Peter Hersey.
Front Immunol, 2020 Mar 27; 11. PMID: 32210968    Free PMC article.
Phylogenetic Quantification of Intratumor Heterogeneity.
Thomas B K Watkins, Roland F Schwarz.
Cold Spring Harb Perspect Med, 2017 Jul 16; 8(4). PMID: 28710259    Free PMC article.
Targeting ERK beyond the boundaries of the kinase active site in melanoma.
Rachel M Sammons, Ranajeet Ghose, Kenneth Y Tsai, Kevin N Dalby.
Mol Carcinog, 2019 Jun 14; 58(9). PMID: 31190430    Free PMC article.
Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety.
Yan Ge, Haiyan Wang, +10 authors, David L Bartlett.
J Immunother Cancer, 2020 Mar 27; 8(1). PMID: 32209602    Free PMC article.
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
Xiaodong Wang, Xiaohui Yang, +21 authors, Shan Gao.
Proc Natl Acad Sci U S A, 2020 Mar 13; 117(12). PMID: 32161124    Free PMC article.
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity.
Alexandra Schnell, Lloyd Bod, Asaf Madi, Vijay K Kuchroo.
Cell Res, 2020 Jan 25; 30(4). PMID: 31974523    Free PMC article.
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.
Marina Ruiz de Galarreta, Erin Bresnahan, +20 authors, Amaia Lujambio.
Cancer Discov, 2019 Jun 13; 9(8). PMID: 31186238    Free PMC article.
Highly Cited.
Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy.
Hongwei Chen, Xin Luan, +7 authors, Duxin Sun.
Nanomedicine (Lond), 2019 Dec 24; 15(1). PMID: 31868112    Free PMC article.
Identification of Small Molecule Enhancers of Immunotherapy for Melanoma.
Christopher Dextras, Myagmarjav Dashnyam, +13 authors, Anju Singh.
Sci Rep, 2020 Apr 02; 10(1). PMID: 32231230    Free PMC article.
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
Bo Gong, Kazuma Kiyotani, +11 authors, Ryohei Katayama.
J Exp Med, 2019 Mar 16; 216(4). PMID: 30872362    Free PMC article.
Highly Cited.
Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
Robin Park, Laercio Lopes, +2 authors, Anwaar Saeed.
Front Oncol, 2020 Apr 08; 10. PMID: 32257944    Free PMC article.
Systematic Review.
Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
Alice Mougel, Magali Terme, Corinne Tanchot.
Front Immunol, 2019 Mar 30; 10. PMID: 30923527    Free PMC article.
Highly Cited. Review.
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Morgane Denis, Michael Duruisseaux, Marie Brevet, Charles Dumontet.
Front Immunol, 2020 Apr 09; 11. PMID: 32265935    Free PMC article.
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Thaiz Rivera Vargas, Lionel Apetoh.
Front Immunol, 2019 Jun 14; 10. PMID: 31191545    Free PMC article.
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
Ingrid Teige, Linda Mårtensson, Björn L Frendéus.
Front Immunol, 2019 Apr 02; 10. PMID: 30930905    Free PMC article.
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
Kripa Guram, Sangwoo S Kim, +6 authors, Andrew B Sharabi.
Front Immunol, 2019 Apr 03; 10. PMID: 30936880    Free PMC article.
TLR3 Activation of Intratumoral CD103+ Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity.
Emiliano Roselli, Paula Araya, +6 authors, Mariana Maccioni.
Front Immunol, 2019 Apr 06; 10. PMID: 30949170    Free PMC article.
The Tumor Immune Contexture of Prostate Cancer.
Natasha Vitkin, Sarah Nersesian, David Robert Siemens, Madhuri Koti.
Front Immunol, 2019 Apr 16; 10. PMID: 30984182    Free PMC article.
Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.
Barbara Seliger.
Front Immunol, 2019 Jun 11; 10. PMID: 31178856    Free PMC article.
The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer.
John Kwon, Samuel F Bakhoum.
Cancer Discov, 2019 Dec 20; 10(1). PMID: 31852718    Free PMC article.
Highly Cited. Review.
Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy.
Julia Koerner, Dennis Horvath, Marcus Groettrup.
Front Immunol, 2019 Apr 27; 10. PMID: 31024545    Free PMC article.
Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure.
Lorenzo Castagnoli, Francesca De Santis, +4 authors, Serenella M Pupa.
Cells, 2020 Mar 04; 9(3). PMID: 32120774    Free PMC article.
In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
Luigi Fattore, Virginia Campani, +8 authors, Gennaro Ciliberto.
Int J Mol Sci, 2020 Mar 18; 21(6). PMID: 32178301    Free PMC article.
CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.
Alberto L Horenstein, Cristiano Bracci, Fabio Morandi, Fabio Malavasi.
Front Immunol, 2019 May 10; 10. PMID: 31068926    Free PMC article.
New Approaches on Cancer Immunotherapy.
Jong-Ho Cha, Li-Chuan Chan, Min Sup Song, Mien-Chie Hung.
Cold Spring Harb Perspect Med, 2019 Oct 17; 10(8). PMID: 31615865    Free PMC article.
Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
Simone de Leve, Florian Wirsdörfer, Verena Jendrossek.
Front Immunol, 2019 Apr 27; 10. PMID: 31024543    Free PMC article.
Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.
Kirill Peskov, Ivan Azarov, +3 authors, Gabriel Helmlinger.
Front Immunol, 2019 May 28; 10. PMID: 31134058    Free PMC article.
Prothymosin-α enhances phosphatase and tensin homolog expression and binds with tripartite motif-containing protein 21 to regulate Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling in human bladder cancer.
Yuh-Shyan Tsai, Yeong-Chin Jou, +3 authors, Tzong-Shin Tzai.
Cancer Sci, 2019 Feb 06; 110(4). PMID: 30719818    Free PMC article.
Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling.
Koen A Marijt, Marjolein Sluijter, +4 authors, Thorbald van Hall.
J Immunother Cancer, 2019 Jun 15; 7(1). PMID: 31196219    Free PMC article.
Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment.
Yuting Zhang, Liu Guoqiang, Miaomiao Sun, Xin Lu.
Cancer Biol Med, 2020 Apr 17; 17(1). PMID: 32296575    Free PMC article.
DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade.
Guo-Liang Chew, Amy E Campbell, +4 authors, Robert K Bradley.
Dev Cell, 2019 Jul 23; 50(5). PMID: 31327741    Free PMC article.
Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer.
Eda K Holl, Victoria N Frazier, +3 authors, Smita K Nair.
Front Immunol, 2019 Aug 17; 10. PMID: 31417550    Free PMC article.
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
Rachel Grosser, Leonid Cherkassky, Navin Chintala, Prasad S Adusumilli.
Cancer Cell, 2019 Nov 13; 36(5). PMID: 31715131    Free PMC article.
Gut Microbiome and the Response to Immunotherapy in Cancer.
Andreea Lucia Stancu.
Discoveries (Craiova), 2018 Sep 30; 6(3). PMID: 32309602    Free PMC article.
The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.
Jun Gong, Alexander Chehrazi-Raffle, +3 authors, Ravi Salgia.
Clin Transl Med, 2019 Mar 20; 8(1). PMID: 30887236    Free PMC article.
Highly Cited. Review.
The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review.
Barbara Seliger.
Front Immunol, 2019 Sep 27; 10. PMID: 31555274    Free PMC article.
TNF-α inhibitor reduces drug-resistance to anti-PD-1: A mathematical model.
Xiulan Lai, Wenrui Hao, Avner Friedman.
PLoS One, 2020 Apr 21; 15(4). PMID: 32310956    Free PMC article.
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition.
Jenny H Lee, Elena Shklovskaya, +15 authors, Helen Rizos.
Nat Commun, 2020 Apr 22; 11(1). PMID: 32312968    Free PMC article.
Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy.
Clayton Hardman, Stephen Ho, +6 authors, Paul A Wender.
Nat Commun, 2020 Apr 22; 11(1). PMID: 32312992    Free PMC article.
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Luisa Chocarro de Erauso, Miren Zuazo, +8 authors, David Escors.
Front Pharmacol, 2020 Apr 23; 11. PMID: 32317979    Free PMC article.
Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study.
Tong Xie, Yiqiang Liu, +6 authors, Zhi Peng.
J Immunother, 2020 Mar 07; 43(4). PMID: 32134806    Free PMC article.
Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.
Samarth Hegde, Varintra E Krisnawan, +16 authors, David G DeNardo.
Cancer Cell, 2020 Mar 19; 37(3). PMID: 32183949    Free PMC article.
Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response.
Isabella McGoverne, Jenny Dunn, +3 authors, Sudha Rao.
BMC Immunol, 2020 Apr 23; 21(1). PMID: 32316916    Free PMC article.
CAR T cell therapy: newer approaches to counter resistance and cost.
Rajesh Kumar Yadav, Asgar Ali, +6 authors, Sadhana Sharma.
Heliyon, 2020 Apr 24; 6(4). PMID: 32322738    Free PMC article.
Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
Hong Qiu, Patrick M Zmina, +2 authors, Barbara Bedogni.
Cancer Lett, 2018 Jul 24; 434. PMID: 30036609    Free PMC article.
Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.
Xue Bai, David E Fisher, Keith T Flaherty.
Nat Rev Clin Oncol, 2019 Apr 11; 16(9). PMID: 30967646    Free PMC article.
Highly Cited. Review.
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
Harriet M Kluger, Hussein A Tawbi, +22 authors, Ryan J Sullivan.
J Immunother Cancer, 2020 Apr 03; 8(1). PMID: 32238470    Free PMC article.
Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.
Xiaoguang Wang, Brittany C Waschke, +5 authors, Jing H Wang.
Cancer Immunol Res, 2019 Jun 27; 7(8). PMID: 31235619    Free PMC article.
Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer.
Tae Hyun Kang, Sang Taek Jung.
Biomolecules, 2020 Mar 04; 10(3). PMID: 32121592    Free PMC article.
Immunotherapy in Renal Cell Carcinoma: The Future Is Now.
Antoine Deleuze, Judikaël Saout, +9 authors, Solène-Florence Kammerer-Jacquet.
Int J Mol Sci, 2020 Apr 09; 21(7). PMID: 32260578    Free PMC article.
PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.
Goran Micevic, Durga Thakral, Meaghan McGeary, Marcus W Bosenberg.
Pigment Cell Melanoma Res, 2018 Oct 22; 32(3). PMID: 30343532    Free PMC article.
YAP/TAZ Signaling and Resistance to Cancer Therapy.
Chan D K Nguyen, Chunling Yi.
Trends Cancer, 2019 Jun 09; 5(5). PMID: 31174841    Free PMC article.
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.
Vancheswaran Gopalakrishnan, Beth A Helmink, +2 authors, Jennifer A Wargo.
Cancer Cell, 2018 Apr 11; 33(4). PMID: 29634945    Free PMC article.
Highly Cited. Review.
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
Balamayoora Theivanthiran, Kathy S Evans, +12 authors, Brent A Hanks.
J Clin Invest, 2020 Feb 06; 130(5). PMID: 32017708    Free PMC article.
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Yuankai Shi, Hang Su, +18 authors, Bo Peng.
EBioMedicine, 2020 Apr 19; 54. PMID: 32304999    Free PMC article.
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
A J Robert McGray, Ruea-Yea Huang, +9 authors, Kunle Odunsi.
J Immunother Cancer, 2019 Jul 19; 7(1). PMID: 31315674    Free PMC article.
Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.
Zuyuan Lin, Di Lu, +2 authors, Xiao Xu.
Am J Cancer Res, 2020 May 06; 10(4). PMID: 32368387    Free PMC article.
Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer.
Qingzhu Jia, Luting Chiu, +14 authors, Bo Zhu.
Adv Sci (Weinh), 2020 May 10; 7(9). PMID: 32382482    Free PMC article.
Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells.
Sisi Deng, Zhichen Sun, +8 authors, Hua Peng.
JCI Insight, 2020 Apr 10; 5(7). PMID: 32271164    Free PMC article.
Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Aleksi Suo, Yin Chan, +7 authors, Tina Cheng.
Oncologist, 2020 Feb 13; 25(5). PMID: 32048768    Free PMC article.
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells.
Rowa Y Alhabbab.
Front Genet, 2020 May 12; 11. PMID: 32391048    Free PMC article.
What does not kill you makes you stronger: surviving anti-cancer therapies by cytoskeletal remodeling and Myosin II reactivation.
Jose L Orgaz, Victoria Sanz-Moreno.
Mol Cell Oncol, 2020 May 12; 7(3). PMID: 32391428    Free PMC article.
Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy.
Rongqing Zhao, Qian Xiao, +7 authors, Le Sun.
Antib Ther, 2020 May 12; 3(2). PMID: 32391516    Free PMC article.
NK Cell-Based Immunotherapies in Cancer.
Min Hwa Shin, Junghee Kim, +3 authors, Kyung-Mi Lee.
Immune Netw, 2020 May 13; 20(2). PMID: 32395366    Free PMC article.
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.
Alberto Puccini, Francesca Battaglin, +2 authors, Mohamed E Salem.
J Immunother Cancer, 2020 May 13; 8(1). PMID: 32393474    Free PMC article.
The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.
Daniel J Olson, Jason J Luke.
Immunotherapy, 2019 Feb 08; 11(3). PMID: 30730272    Free PMC article.
Future Challenges in Cancer Resistance to Immunotherapy.
Marit J van Elsas, Thorbald van Hall, Sjoerd H van der Burg.
Cancers (Basel), 2020 Apr 16; 12(4). PMID: 32290124    Free PMC article.
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.
Teresa Amaral, Olivia Seeber, +8 authors, Claus Garbe.
Cancers (Basel), 2020 Apr 26; 12(4). PMID: 32331243    Free PMC article.
Computational models of melanoma.
Marco Albrecht, Philippe Lucarelli, Dagmar Kulms, Thomas Sauter.
Theor Biol Med Model, 2020 May 16; 17(1). PMID: 32410672    Free PMC article.
Normalization Cancer Immunotherapy for Melanoma.
Matthew D Vesely, Lieping Chen.
J Invest Dermatol, 2020 Feb 25; 140(6). PMID: 32092349    Free PMC article.
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.
Hanjie Li, Anne M van der Leun, +15 authors, Ido Amit.
Cell, 2019 Jan 01; 176(4). PMID: 30595452    Free PMC article.
Highly Cited.
MHC-I genotype and tumor mutational burden predict response to immunotherapy.
Aaron M Goodman, Andrea Castro, +9 authors, Razelle Kurzrock.
Genome Med, 2020 May 21; 12(1). PMID: 32430031    Free PMC article.
Hypoxia-Driven Immune Escape in the Tumor Microenvironment.
Alyssa Vito, Nader El-Sayes, Karen Mossman.
Cells, 2020 Apr 23; 9(4). PMID: 32316260    Free PMC article.
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Satya Das, Audrey Allen, Jordan Berlin.
Clin Colorectal Cancer, 2020 Mar 09; 19(2). PMID: 32146081    Free PMC article.
pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity.
Janessa Wehr, Eden L Sikorski, +6 authors, Damien Thévenin.
J Med Chem, 2020 Mar 21; 63(7). PMID: 32196345    Free PMC article.
Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Di Chen, Gaopeng Li, +10 authors, Liangfu Zhou.
J Immunother Cancer, 2020 May 28; 8(1). PMID: 32457124    Free PMC article.
The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Cinzia Solinas, Chunyan Gu-Trantien, Karen Willard-Gallo.
ESMO Open, 2020 Jun 10; 5(1). PMID: 32516116    Free PMC article.
The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors.
Evangelos Koustas, Panagiotis Sarantis, Athanasios G Papavassiliou, Michalis V Karamouzis.
Biomolecules, 2020 Apr 30; 10(5). PMID: 32344837    Free PMC article.
Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition.
Lauren E Stopfer, Joshua M Mesfin, +2 authors, Forest M White.
Nat Commun, 2020 Jun 04; 11(1). PMID: 32488085    Free PMC article.
In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
Ping Du, Ting Hu, +2 authors, Lihong Liu.
Cancer Sci, 2020 Apr 01; 111(6). PMID: 32227409    Free PMC article.
Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
Teresa Troiani, Emilio Francesco Giunta, +6 authors, Simona Romano.
Br J Cancer, 2020 Apr 23; 122(12). PMID: 32317723    Free PMC article.
Acquired Resistance to Immune Checkpoint Blockade Therapies.
Xianda Zhao, Dechen Wangmo, Matthew Robertson, Subbaya Subramanian.
Cancers (Basel), 2020 May 10; 12(5). PMID: 32380703    Free PMC article.
Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Jörg Hänze, Moritz Wegner, +2 authors, Axel Hegele.
Target Oncol, 2020 Jun 05; 15(3). PMID: 32495158    Free PMC article.
Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy.
Feng Xie, Jianjun Zhang, +25 authors, Tian Xia.
Clin Cancer Res, 2020 Jan 09; 26(12). PMID: 31911545    Free PMC article.
Assessment of IFNγ responsiveness in patient-derived xenografts.
Jordan J Cardenas, Camila Robles-Oteiza, Katerina Politi.
Methods Enzymol, 2020 Jan 18; 631. PMID: 31948560    Free PMC article.
Induction of DNMT3B by PGE2 and IL6 at Distant Metastatic Sites Promotes Epigenetic Modification and Breast Cancer Colonization.
Jae Young So, Nicolas Skrypek, +14 authors, Li Yang.
Cancer Res, 2020 Apr 09; 80(12). PMID: 32265226    Free PMC article.
Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
Eun-Hye Kim, Masuki Kawamoto, +3 authors, Hideyuki Miyatake.
Int J Mol Sci, 2020 May 28; 21(10). PMID: 32455628    Free PMC article.
Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence.
Aurora Mirabile, Licia Rivoltini, +8 authors, Vanesa Gregorc.
Cancers (Basel), 2020 May 08; 12(5). PMID: 32375310    Free PMC article.
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma.
Xiaoguang Wang, Brittany C Waschke, +3 authors, Jing H Wang.
Protein Cell, 2020 Mar 13; 11(7). PMID: 32162275    Free PMC article.
AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.
Ishani Das, Helge Gad, +9 authors, Ulrika Warpman Berglund.
Cell Death Differ, 2020 Jan 11; 27(7). PMID: 31919461    Free PMC article.
cGAS-STING, an important pathway in cancer immunotherapy.
Minlin Jiang, Peixin Chen, +8 authors, Caicun Zhou.
J Hematol Oncol, 2020 Jun 24; 13(1). PMID: 32571374    Free PMC article.
Real time visualization of cancer cell death, survival and proliferation using fluorochrome-transfected cells in an IncuCyte® imaging system.
Thomas M Lanigan, Stephanie M Rasmussen, +4 authors, Jeffrey H Ruth.
J Biol Methods, 2020 Jun 25; 7(2). PMID: 32577423    Free PMC article.
Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics.
Colin G Buss, Sangeeta N Bhatia.
Proc Natl Acad Sci U S A, 2020 Jun 05; 117(24). PMID: 32493746    Free PMC article.
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
Amblessed E Onuma, Hongji Zhang, +3 authors, Allan Tsung.
Gene Expr, 2020 Apr 29; 20(1). PMID: 32340652    Free PMC article.
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
Magdalena Olbryt, Marcin Rajczykowski, Wiesława Widłak.
Int J Mol Sci, 2020 Jun 11; 21(11). PMID: 32517213    Free PMC article.
Profiles of Immune Infiltration and Prognostic Immunoscore in Lung Adenocarcinoma.
Yanyan Li, Liping Tao, Weiyang Cai.
Biomed Res Int, 2020 Jul 01; 2020. PMID: 32596334    Free PMC article.
Systems approach to rational combination therapy: PARP inhibitors.
Chaoyang Sun, Yong Fang, +2 authors, Gordon B Mills.
Biochem Soc Trans, 2020 May 08; 48(3). PMID: 32379297    Free PMC article.
Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.
Min-Hee Oh, Im-Hong Sun, +17 authors, Jonathan D Powell.
J Clin Invest, 2020 Apr 24; 130(7). PMID: 32324593    Free PMC article.
Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
Jian Cao, Qin Yan.
Trends Cancer, 2020 Jul 02; 6(7). PMID: 32610068    Free PMC article.
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.
Shinichiro Kato, Qing Yu Weng, +20 authors, David E Fisher.
Cancer Discov, 2020 Apr 10; 10(7). PMID: 32269030    Free PMC article.
The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma.
Ragia Aly, Sachin Gupta, Rashmika Potdar.
Cureus, 2020 Jul 04; 12(6). PMID: 32617246    Free PMC article.
Myeloid Cells in Circulation and Tumor Microenvironment of Colorectal Cancer Patients with Early and Advanced Disease Stages.
Salman M Toor, Sarah Khalaf, +2 authors, Eyad Elkord.
J Immunol Res, 2020 Jul 07; 2020. PMID: 32626789    Free PMC article.
Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma.
Andre van der Westhuizen, Naomi Knoblauch, +3 authors, Nikola A Bowden.
Medicine (Baltimore), 2020 Jun 23; 99(25). PMID: 32569203    Free PMC article.
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.
Ilyas Sahin, Shengliang Zhang, +4 authors, Wafik S El-Deiry.
Cell Death Discov, 2020 Jul 14; 6. PMID: 32655895    Free PMC article.
Chemotherapy but Not the Tumor Draining Lymph Nodes Determine the Immunotherapy Response in Secondary Tumors.
Xianda Zhao, Beminet Kassaye, +2 authors, Subbaya Subramanian.
iScience, 2020 Apr 29; 23(5). PMID: 32344378    Free PMC article.
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses.
Patricia M Santos, Juraj Adamik, +6 authors, Lisa H Butterfield.
J Exp Med, 2020 May 06; 217(7). PMID: 32369107    Free PMC article.
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Florent Peyraud, Antoine Italiano.
Cancers (Basel), 2020 Jun 13; 12(6). PMID: 32526888    Free PMC article.
Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
Lingyun Liu, Jinghai Hu, +4 authors, Fuzhe Ma.
Aging (Albany NY), 2020 Jun 23; 12(12). PMID: 32570217    Free PMC article.
Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges.
Shyambabu Chaurasiya, Yuman Fong, Susanne G Warner.
Cancers (Basel), 2020 Jul 02; 12(6). PMID: 32604787    Free PMC article.
Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma.
Kevin C Miller, Ashish V Chintakuntlawar, +6 authors, Keith C Bible.
J Endocr Soc, 2020 Jul 16; 4(7). PMID: 32666013    Free PMC article.
Toward Systems Biomarkers of Response to Immune Checkpoint Blockers.
Óscar Lapuente-Santana, Federica Eduati.
Front Oncol, 2020 Jul 17; 10. PMID: 32670886    Free PMC article.
Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.
Christopher M Hartshorn, Michelle S Bradbury, +6 authors, Piotr Grodzinski.
ACS Nano, 2017 Dec 20; 12(1). PMID: 29257865    Free PMC article.
Characterization of a Myeloid Activation Signature that Correlates with Survival in Melanoma Patients.
Mirela Kremenovic, Nives Rombini, +4 authors, Mirjam Schenk.
Cancers (Basel), 2020 Jun 04; 12(6). PMID: 32486450    Free PMC article.
Integrating the Tumor Microenvironment into Cancer Therapy.
Sabina Sanegre, Federico Lucantoni, +3 authors, Tomás Álvaro Naranjo.
Cancers (Basel), 2020 Jul 01; 12(6). PMID: 32599891    Free PMC article.
Recombinant Costimulatory Fusion Proteins as Functional Immunomodulators Enhance Antitumor Activity in Murine B16F10 Melanoma.
Huaman Cai, Wenfang Wang, +4 authors, Rongxiu Li.
Vaccines (Basel), 2020 May 20; 8(2). PMID: 32423130    Free PMC article.
Role of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance.
Patrick Santos, Fausto Almeida.
Cells, 2020 Jun 18; 9(6). PMID: 32545155    Free PMC article.
Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.
Reem Saleh, Salman M Toor, +2 authors, Eyad Elkord.
Genes (Basel), 2020 Jul 04; 11(6). PMID: 32616706    Free PMC article.
How the ageing microenvironment influences tumour progression.
Mitchell Fane, Ashani T Weeraratna.
Nat Rev Cancer, 2019 Dec 15; 20(2). PMID: 31836838    Free PMC article.
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.
Orit Rozenblatt-Rosen, Aviv Regev, +35 authors, Human Tumor Atlas Network.
Cell, 2020 Apr 18; 181(2). PMID: 32302568    Free PMC article.
Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Sjoerd T T Schetters, Ernesto Rodriguez, +5 authors, Yvette Van Kooyk.
J Immunother Cancer, 2020 Jul 22; 8(2). PMID: 32690667    Free PMC article.
Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors.
Diwakar Davar, Hassane M Zarour.
Methods Mol Biol, 2019 Sep 11; 2055. PMID: 31502146    Free PMC article.
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Cai Zhang, Yuxia Liu.
Front Immunol, 2020 Jul 28; 11. PMID: 32714324    Free PMC article.
Coronavirus infection and immune system: An insight of COVID-19 in cancer patients.
Alice Indini, Erika Rijavec, +5 authors, Francesco Grossi.
Crit Rev Oncol Hematol, 2020 Jul 28; 153. PMID: 32711241    Free PMC article.
Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok.
Science, 2018 Mar 24; 359(6382). PMID: 29567705    Free PMC article.
Highly Cited. Review.
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Qianmei Yang, Gang Shi, +20 authors, Hongxin Deng.
Theranostics, 2020 Jul 30; 10(18). PMID: 32724476    Free PMC article.
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials.
Bin Zhao, Hong Zhao, Jiaxin Zhao.
Ther Adv Med Oncol, 2020 Jul 31; 12. PMID: 32728392    Free PMC article.
Nanomedicine and macroscale materials in immuno-oncology.
Qingxue Sun, Matthias Barz, +5 authors, Yang Shi.
Chem Soc Rev, 2018 Nov 23; 48(1). PMID: 30465669    Free PMC article.
A brief review concerning Chimeric Antigen Receptors T cell therapy.
Ling-Lin Li, Hong-Ling Yuan, +2 authors, Ren-Chao Zou.
J Cancer, 2020 Aug 04; 11(18). PMID: 32742489    Free PMC article.
Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients.
Liuxi Chen, Xingxing Huang, +17 authors, Xinbing Sui.
J Cancer, 2020 Aug 04; 11(18). PMID: 32742491    Free PMC article.
Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions.
Satoshi Tobita, Yuhei Kinehara, +10 authors, Isao Tachibana.
Thorac Cancer, 2020 Jun 23; 11(8). PMID: 32567218    Free PMC article.
Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.
Zong Sheng Guo, Michael T Lotze, +2 authors, Xiao-Tong Song.
Biomedicines, 2020 Jul 16; 8(7). PMID: 32664210    Free PMC article.
Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.
Julia Festag, Tamara Thelemann, +4 authors, Richard Klar.
Mol Ther Nucleic Acids, 2020 Aug 03; 21. PMID: 32739778    Free PMC article.
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Xiangmeng Wang, Po Yee Mak, +9 authors, Bing Z Carter.
Mol Cancer Ther, 2020 May 15; 19(8). PMID: 32404407    Free PMC article.
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
Davis Y Torrejon, Gabriel Abril-Rodriguez, +18 authors, Antoni Ribas.
Cancer Discov, 2020 May 30; 10(8). PMID: 32467343    Free PMC article.
Organoid Models of Tumor Immunology.
Kanako Yuki, Ning Cheng, Michitaka Nakano, Calvin J Kuo.
Trends Immunol, 2020 Jul 14; 41(8). PMID: 32654925    Free PMC article.
Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment.
Zhou Jiang, Jennifer L Hsu, +2 authors, Mien-Chie Hung.
Front Oncol, 2020 Aug 11; 10. PMID: 32775303    Free PMC article.
Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer.
Kyoung-Ho Pyo, Sun Min Lim, +13 authors, Byoung Chul Cho.
J Immunother Cancer, 2020 Jul 31; 8(2). PMID: 32727812    Free PMC article.
Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer Immunotherapy.
Peter D Koch, Christopher B Rodell, +2 authors, Ralph Weissleder.
Cell Chem Biol, 2020 Jan 07; 27(1). PMID: 31902676    Free PMC article.
Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors.
Magalie Dosset, Elodie Lauret-Marie Joseph, Thaiz Rivera Vargas, Lionel Apetoh.
Cells, 2020 Jul 28; 9(7). PMID: 32707692    Free PMC article.
Evaluation of the upregulation and surface expression of hypoxanthine guanine phosphoribosyltransferase in acute lymphoblastic leukemia and Burkitt's B cell lymphoma.
Michelle H Townsend, Zac E Ence, +6 authors, Kim L O'Neill.
Cancer Cell Int, 2020 Aug 13; 20. PMID: 32782434    Free PMC article.
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Julia Boshuizen, David W Vredevoogd, +16 authors, Daniel S Peeper.
Nat Commun, 2020 Aug 10; 11(1). PMID: 32770055    Free PMC article.
Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
Rilan Bai, Naifei Chen, +4 authors, Jiuwei Cui.
Front Oncol, 2020 Aug 15; 10. PMID: 32793461    Free PMC article.
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Qingyang Lei, Dan Wang, +2 authors, Yi Zhang.
Front Cell Dev Biol, 2020 Aug 15; 8. PMID: 32793604    Free PMC article.
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Luis Felipe Campesato, Sadna Budhu, +15 authors, Jedd D Wolchok.
Nat Commun, 2020 Aug 13; 11(1). PMID: 32782249    Free PMC article.
Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
Limei Zhong, Linling Xie, +4 authors, Yufeng Liu.
BMC Cancer, 2020 Aug 18; 20(1). PMID: 32799825    Free PMC article.
Long noncoding RNA loss in immune suppression in cancer.
Qingsong Hu, Sergey D Egranov, Chunru Lin, Liuqing Yang.
Pharmacol Ther, 2020 Jun 01; 213. PMID: 32473960    Free PMC article.
Spontaneous Tumor Regression in Tasmanian Devils Associated with RASL11A Activation.
Mark J Margres, Manuel Ruiz-Aravena, +13 authors, Andrew Storfer.
Genetics, 2020 Jun 20; 215(4). PMID: 32554701    Free PMC article.
Elevated long noncoding RNA MALAT-1 expression is predictive of poor prognosis in patients with breast cancer: a meta-analysis.
Yanyan Wang, Yujie Zhang, +4 authors, Suzhan Zhang.
Biosci Rep, 2020 Jul 24; 40(8). PMID: 32700729    Free PMC article.
Systematic Review.
Past, Present, and Future of Anticancer Nanomedicine.
Kyungeun Kim, Dongwoo Khang.
Int J Nanomedicine, 2020 Aug 22; 15. PMID: 32821098    Free PMC article.
Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting.
Joana Vieira de Castro, Céline S Gonçalves, Adília Hormigo, Bruno M Costa.
Int J Mol Sci, 2020 Jul 30; 21(15). PMID: 32722427    Free PMC article.
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy.
Elisabet Cuyàs, Sara Verdura, +4 authors, Javier A Menendez.
Cancers (Basel), 2020 Jul 08; 12(7). PMID: 32630618    Free PMC article.
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy.
Annelisa M Cornel, Iris L Mimpen, Stefan Nierkens.
Cancers (Basel), 2020 Jul 08; 12(7). PMID: 32630675    Free PMC article.
New tools to prevent cancer growth and spread: a 'Clever' approach.
Maija Hollmén, Carlos R Figueiredo, Sirpa Jalkanen.
Br J Cancer, 2020 Jul 01; 123(4). PMID: 32595212    Free PMC article.
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.
Shin Foong Ngiow, Arabella Young.
Front Immunol, 2020 Aug 28; 11. PMID: 32849557    Free PMC article.
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
Paola De Cicco, Giuseppe Ercolano, Angela Ianaro.
Front Immunol, 2020 Aug 28; 11. PMID: 32849585    Free PMC article.
Immune Landscape of the Tumor Microenvironment Identifies Prognostic Gene Signature CD4/CD68/CSF1R in Osteosarcoma.
Yi-Jiang Song, Yanyang Xu, +8 authors, Jin Wang.
Front Oncol, 2020 Aug 28; 10. PMID: 32850346    Free PMC article.
Mechanisms of Cancer Resistance to Immunotherapy.
Rilan Bai, Naifei Chen, +5 authors, Jiuwei Cui.
Front Oncol, 2020 Aug 28; 10. PMID: 32850400    Free PMC article.
Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade.
Bo Ryeong Lee, Sehyun Chae, +8 authors, Sang-Jun Ha.
JCI Insight, 2020 Jun 20; 5(14). PMID: 32554931    Free PMC article.
[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
Sixuan Wu, Chunhong Hu, +2 authors, Ping Liu.
Zhongguo Fei Ai Za Zhi, 2019 Jul 19; 22(7). PMID: 31315783    Free PMC article.
Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
Dominic Maggio, Winson S Ho, +8 authors, Zhengping Zhuang.
J Neurooncol, 2020 Apr 29; 148(2). PMID: 32342332    Free PMC article.
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.
A Ari Hakimi, Kyrollis Attalla, +14 authors, Robert J Motzer.
Nat Commun, 2020 Aug 21; 11(1). PMID: 32820162    Free PMC article.
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.
Vivek Verma, Rajeev K Shrimali, +25 authors, Samir N Khleif.
Nat Immunol, 2019 Jul 31; 20(9). PMID: 31358999    Free PMC article.
Highly Cited.
Nanoengineered targeting strategy for cancer immunotherapy.
Wei-Min Yin, Yu-Wei Li, Yun-Qing Gu, Min Luo.
Acta Pharmacol Sin, 2020 May 14; 41(7). PMID: 32398683    Free PMC article.
EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment.
Yaqi Tang, Simon Durand, Stéphane Dalle, Julie Caramel.
Cancers (Basel), 2020 Aug 08; 12(8). PMID: 32759677    Free PMC article.
Anti-cancer Immunotherapies Targeting Telomerase.
Simone Negrini, Raffaele De Palma, Gilberto Filaci.
Cancers (Basel), 2020 Aug 19; 12(8). PMID: 32806719    Free PMC article.
Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad.
Augusto Bleve, Barbara Durante, Antonio Sica, Francesca Maria Consonni.
Int J Mol Sci, 2020 Aug 23; 21(16). PMID: 32823961    Free PMC article.
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge.
Federica Marmorino, Alessandra Boccaccino, +2 authors, Chiara Cremolini.
Cancers (Basel), 2020 Aug 23; 12(8). PMID: 32824490    Free PMC article.
Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
Chaoqi Zhang, Guochao Zhang, +6 authors, Jie He.
EBioMedicine, 2020 Aug 28; 59. PMID: 32853987    Free PMC article.
Progress in hepatectomy for hepatocellular carcinoma and peri-operation management.
Hao Chen, Weidong Jia.
Genes Dis, 2020 Sep 05; 7(3). PMID: 32884986    Free PMC article.
Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report.
Yiruo Zhang, Mei Zhao, +2 authors, Yingying Du.
Thorac Cancer, 2020 Jul 14; 11(9). PMID: 32656988    Free PMC article.
Multi-omics Data Analyses Construct TME and Identify the Immune-Related Prognosis Signatures in Human LUAD.
Yuwei Zhang, Minglei Yang, +6 authors, Qi Liao.
Mol Ther Nucleic Acids, 2020 Aug 18; 21. PMID: 32805489    Free PMC article.
The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma.
Joji Nagasaki, Yosuke Togashi, +10 authors, Hiroyoshi Nishikawa.
Blood Adv, 2020 Sep 02; 4(17). PMID: 32870971    Free PMC article.
CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.
Yu Chen, Yingying Huang, +13 authors, Chuanben Chen.
Front Immunol, 2020 Sep 10; 11. PMID: 32903763    Free PMC article.
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer.
Debarati Banik, Satish Noonepalle, +11 authors, Alejandro Villagra.
Cancer Res, 2020 Jul 02; 80(17). PMID: 32605998    Free PMC article.
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.
Yang Gao, Naoe Taira Nihira, +24 authors, Wenyi Wei.
Nat Cell Biol, 2020 Aug 26; 22(9). PMID: 32839551    Free PMC article.
Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy.
Elham Beyranvand Nejad, Camilla Labrie, +12 authors, Sjoerd H van der Burg.
J Immunother Cancer, 2020 Sep 03; 8(2). PMID: 32873723    Free PMC article.
Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy.
Kin Man Au, Steven I Park, Andrew Z Wang.
Sci Adv, 2020 Sep 15; 6(27). PMID: 32923587    Free PMC article.
ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy.
Masoud Sotoudeh, Ramin Shakeri, +3 authors, Mahmood Naderi.
Cancer Immunol Immunother, 2019 Sep 15; 68(10). PMID: 31520110    Free PMC article.
Biomarkers of immunotherapy in non-small cell lung cancer.
Lingling Wang, Yue Hu, +2 authors, Xiaochen Wang.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934707    Free PMC article.
Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy.
Romain Daillère, Lisa Derosa, +14 authors, Laurence Zitvogel.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934879    Free PMC article.
Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors.
Romain Daillère, Bertrand Routy, +18 authors, Lisa Derosa.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934888    Free PMC article.
Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis.
Baihui Li, Bailu Zhang, +6 authors, Lili Yang.
Oncoimmunology, 2020 Sep 18; 9(1). PMID: 32939323    Free PMC article.
Overcoming resistance to immunotherapy by teaching old drugs new tricks.
John M Perry, Linheng Li.
Mol Cell Oncol, 2020 Sep 19; 7(5). PMID: 32944648    Free PMC article.
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors.
Sangtian Liu, Fei Zhou, +16 authors, Caicun Zhou.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953484    Free PMC article.
Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets.
Luis F Campesato, Chien-Huan Weng, Taha Merghoub.
Ann Transl Med, 2020 Sep 22; 8(16). PMID: 32953831    Free PMC article.
Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles.
Bi Wang, Simon Van Herck, +12 authors, Yang Shi.
J Am Chem Soc, 2020 Jun 12; 142(28). PMID: 32524819    Free PMC article.
Sparse Linear Discriminant Analysis using the Prior-Knowledge-Guided Block Covariance Matrix.
Jin Hyun Nam, Donguk Kim, Dongjun Chung.
Chemometr Intell Lab Syst, 2020 Sep 25; 206. PMID: 32968333    Free PMC article.
Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A.
Hailing Lu, Alec Betancur, Michael Chen, Jan H Ter Meulen.
Front Oncol, 2020 Sep 26; 10. PMID: 32974162    Free PMC article.
A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer.
Christopher J LaRocca, Susanne G Warner.
Biomedicines, 2018 Nov 08; 6(4). PMID: 30400571    Free PMC article.
Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment.
Javed Mahmood, Hem D Shukla, +6 authors, Zeljko Vujaskovic.
Cancers (Basel), 2018 Nov 30; 10(12). PMID: 30486519    Free PMC article.
Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy.
Meghan Leary, Sarah Heerboth, Karolina Lapinska, Sibaji Sarkar.
Cancers (Basel), 2018 Dec 07; 10(12). PMID: 30518036    Free PMC article.
The Sweet Surrender: How Myeloid Cell Metabolic Plasticity Shapes the Tumor Microenvironment.
Je Lin Sieow, Sin Yee Gun, Siew Cheng Wong.
Front Cell Dev Biol, 2019 Jan 09; 6. PMID: 30619850    Free PMC article.
Transforming of the Tumor Microenvironment: Implications for TGF-β Inhibition in the Context of Immune-Checkpoint Therapy.
Stefanie Löffek.
J Oncol, 2019 Jan 12; 2018. PMID: 30631358    Free PMC article.
Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer.
Jennifer A Bridge, James C Lee, +2 authors, Jeffrey A Bluestone.
Front Med (Lausanne), 2019 Jan 12; 5. PMID: 30631766    Free PMC article.
From therapeutic antibodies to immune complex vaccines.
Xuan-Yi Wang, Bin Wang, Yu-Mei Wen.
NPJ Vaccines, 2019 Jan 25; 4. PMID: 30675393    Free PMC article.
PKR: A Kinase to Remember.
Shunit Gal-Ben-Ari, Iliana Barrera, Marcelo Ehrlich, Kobi Rosenblum.
Front Mol Neurosci, 2019 Jan 29; 11. PMID: 30686999    Free PMC article.
Highly Cited. Review.
Recent updates on cancer immunotherapy.
Ming Liu, Fukun Guo.
Precis Clin Med, 2019 Jan 29; 1(2). PMID: 30687562    Free PMC article.
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.
Hansol Lee, Camelia Quek, +19 authors, James S Wilmott.
Oncoimmunology, 2019 Feb 05; 8(2). PMID: 30713793    Free PMC article.
Pre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanoma.
Hector Terán-Navarro, Ricardo Calderon-Gonzalez, +13 authors, Carmen Álvarez-Domínguez.
Oncoimmunology, 2019 Feb 05; 8(2). PMID: 30713801    Free PMC article.
VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy.
Juan-Manuel Hernandez-Martinez, Edgar Vergara, +2 authors, Oscar Arrieta.
J Thorac Dis, 2019 Feb 13; 10(12). PMID: 30746169    Free PMC article.
Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles.
Carlos Aya-Bonilla, Elin S Gray, +7 authors, Mel Ziman.
Cancers (Basel), 2019 Feb 17; 11(2). PMID: 30769764    Free PMC article.
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.
Hélène Blons, Simon Garinet, Pierre Laurent-Puig, Jean-Baptiste Oudart.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775025    Free PMC article.
Metastatic prostate cancer remains incurable, why?
Liang Dong, Richard C Zieren, +2 authors, Kenneth J Pienta.
Asian J Urol, 2019 Feb 19; 6(1). PMID: 30775246    Free PMC article.
On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy.
Benjamin Y Kong, Holly Bolton, +3 authors, Georgina J Clark.
Front Oncol, 2019 Feb 23; 9. PMID: 30788290    Free PMC article.
Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System.
Shweta Joshi, Donald L Durden.
J Oncol, 2019 Mar 12; 2019. PMID: 30853982    Free PMC article.
Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model.
Damini Chand, Deepika Dhawan, +5 authors, Xingxing Zang.
Bladder Cancer, 2019 Mar 12; 5(1). PMID: 30854414    Free PMC article.
The gut microbiome, antitumor immunity, and liver cancer.
Kosuke Mima, Hideo Baba.
Hepatobiliary Surg Nutr, 2019 Mar 19; 8(1). PMID: 30881970    Free PMC article.
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.
Chongkai Wang, Prakash Kulkarni, Ravi Salgia.
Mol Ther Oncolytics, 2019 Apr 13; 13. PMID: 30976658    Free PMC article.
An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.
Muhammad Zubair Afzal, Konstantin H Dragnev, Keisuke Shirai.
Ann Transl Med, 2019 Apr 30; 7(Suppl 1). PMID: 31032332    Free PMC article.
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.
Edith Borcoman, Philippe De La Rochere, +13 authors, Eliane Piaggio.
Oncoimmunology, 2019 May 10; 8(5). PMID: 31069145    Free PMC article.
Contribution of Epithelial Plasticity to Therapy Resistance.
Patricia G Santamaría, Gema Moreno-Bueno, Amparo Cano.
J Clin Med, 2019 May 17; 8(5). PMID: 31091749    Free PMC article.
Highly Cited. Review.
Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three A's: Abundance, Activation and Antigen-Delivery.
Aleksandar Murgaski, Pauline M R Bardet, +2 authors, Damya Laoui.
Cancers (Basel), 2019 May 17; 11(5). PMID: 31091774    Free PMC article.
Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.
Fatima Bilal, Anne Montfort, +10 authors, Bruno Ségui.
Front Pharmacol, 2019 May 23; 10. PMID: 31114500    Free PMC article.
Single-cell technologies for profiling T cells to enable monitoring of immunotherapies.
Xingyue An, Navin Varadarajan.
Curr Opin Chem Eng, 2018 Mar 01; 19. PMID: 31131208    Free PMC article.
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.
Praveen K Bommareddy, Andrew Zloza, Samuel D Rabkin, Howard L Kaufman.
Oncoimmunology, 2019 May 31; 8(7). PMID: 31143509    Free PMC article.
Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies.
Ryo Sato, Kosuke Imamura, +13 authors, Takuro Sakagami.
J Clin Med, 2019 May 31; 8(6). PMID: 31146442    Free PMC article.
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.
Veronica Mollica, Vincenzo Di Nunno, +8 authors, Francesco Massari.
Cancers (Basel), 2019 Jun 19; 11(6). PMID: 31207938    Free PMC article.
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent.
Katrijn Broos, Quentin Lecocq, +9 authors, Karine Breckpot.
Cancers (Basel), 2019 Jun 27; 11(6). PMID: 31234464    Free PMC article.
Adverse Events of Oncologic Immunotherapy and Their Management.
Fedricker Diane Barber.
Asia Pac J Oncol Nurs, 2019 Jul 02; 6(3). PMID: 31259216    Free PMC article.
Tetramethylpyrazine Enhances the Antitumor Effect of Paclitaxel by Inhibiting Angiogenesis and Inducing Apoptosis.
Liang Zou, Xiaowei Liu, +4 authors, Jinming Zhang.
Front Pharmacol, 2019 Jul 12; 10. PMID: 31293426    Free PMC article.
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer.
Vasileios Atsaves, Vasiliki Leventaki, George Z Rassidakis, Francois X Claret.
Cancers (Basel), 2019 Jul 26; 11(7). PMID: 31340499    Free PMC article.
Big Data Approaches for Modeling Response and Resistance to Cancer Drugs.
Peng Jiang, William R Sellers, X Shirley Liu.
Annu Rev Biomed Data Sci, 2019 Jul 26; 1. PMID: 31342013    Free PMC article.
Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance.
Maria Laura De Angelis, Federica Francescangeli, Filippo La Torre, Ann Zeuner.
Front Oncol, 2019 Jul 30; 9. PMID: 31355143    Free PMC article.
Highly Cited. Review.
TEIPP peptides: exploration of unTAPped cancer antigens.
Koen A Marijt, Sjoerd H Van Der Burg, Thorbald van Hall.
Oncoimmunology, 2019 Aug 16; 8(8). PMID: 31413908    Free PMC article.
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells.
Nishant Mohan, Salman Hosain, +5 authors, Wen Jin Wu.
Oncoimmunology, 2019 Aug 21; 8(9). PMID: 31428520    Free PMC article.
Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity.
Elie Dheilly, Stefano Majocchi, +9 authors, Krzysztof Masternak.
Antibodies (Basel), 2018 Jan 03; 7(1). PMID: 31544856    Free PMC article.
Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?
Abdullah Al Emran, Hsin-Yi Tseng, +6 authors, Peter Hersey.
Pigment Cell Melanoma Res, 2020 Feb 07; 33(5). PMID: 32027447    Free PMC article.
Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment.
Anton A A Smith, Emily C Gale, +4 authors, Eric A Appel.
Biomacromolecules, 2020 Aug 21; 21(9). PMID: 32816460    Free PMC article.
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.
Yolla Haibe, Ziad El Husseini, Rola El Sayed, Ali Shamseddine.
Int J Mol Sci, 2020 Sep 02; 21(17). PMID: 32867025    Free PMC article.
Systematic Review.
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion.
David H Peng, Bertha Leticia Rodriguez, +13 authors, Don L Gibbons.
Nat Commun, 2020 Sep 11; 11(1). PMID: 32908154    Free PMC article.
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells.
Demet Candas-Green, Bowen Xie, +29 authors, Jian Jian Li.
Nat Commun, 2020 Sep 16; 11(1). PMID: 32929084    Free PMC article.
An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.
A-Ri Shin, Sang-Eun Lee, +3 authors, Tai-Gyu Kim.
Br J Cancer, 2020 Jul 01; 123(6). PMID: 32595211    Free PMC article.
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Mark R Middleton, Christoph Hoeller, +4 authors, Axel Hauschild.
Br J Cancer, 2020 Jul 28; 123(6). PMID: 32713938    Free PMC article.
Thermosensitive Exosome-Liposome Hybrid Nanoparticle-Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer.
Qijun Lv, Lili Cheng, +6 authors, Jie Liu.
Adv Sci (Weinh), 2020 Oct 02; 7(18). PMID: 32999828    Free PMC article.
The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.
Danilo Rocco, Luigi D Gravara, Cesare Gridelli.
Curr Clin Pharmacol, 2019 Aug 11; 15(1). PMID: 31400270    Free PMC article.
Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Xing Li, Lei Wang, +4 authors, Chunxia Su.
Thorac Cancer, 2020 Aug 12; 11(10). PMID: 32779372    Free PMC article.
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.
Kazuhiro Kakimi, Hirokazu Matsushita, +17 authors, Jun Nakajima.
J Immunother Cancer, 2020 Sep 20; 8(2). PMID: 32948652    Free PMC article.
Differential gene expression of tumor-infiltrating CD8+ T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis.
Reem Saleh, Varun Sasidharan Nair, +8 authors, Eyad Elkord.
J Immunother Cancer, 2020 Sep 20; 8(2). PMID: 32948653    Free PMC article.
Treatment of Advanced Melanoma in 2020 and Beyond.
Russell W Jenkins, David E Fisher.
J Invest Dermatol, 2020 Apr 09; 141(1). PMID: 32268150    Free PMC article.
How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
Jinyang Li, Ben Z Stanger.
Cancer Res, 2020 Jun 20; 80(19). PMID: 32554552    Free PMC article.
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy.
Natalia Rodrigues Mantuano, Marina Natoli, Alfred Zippelius, Heinz Läubli.
J Immunother Cancer, 2020 Oct 07; 8(2). PMID: 33020245    Free PMC article.
Conferring receptors on recipient cells with extracellular vesicles for targeted drug delivery.
Zachary Quinn, Wenjun Mao, +2 authors, Yuan Wan.
Bioact Mater, 2020 Oct 08; 6(3). PMID: 33024896    Free PMC article.
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence.
Xingwu Zhou, Moyuan Qu, +9 authors, Ali Khademhosseini.
Adv Sci (Weinh), 2020 Oct 13; 7(19). PMID: 33042756    Free PMC article.
m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy.
Lingling Wang, Hui Hui, +5 authors, Tariq M Rana.
EMBO J, 2020 Sep 24; 39(20). PMID: 32964498    Free PMC article.
Deep phylogeny of cancer drivers and compensatory mutations.
Nash D Rochman, Yuri I Wolf, Eugene V Koonin.
Commun Biol, 2020 Oct 04; 3(1). PMID: 33009502    Free PMC article.
Biomarker-guided therapy for colorectal cancer: strength in complexity.
Anita Sveen, Scott Kopetz, Ragnhild A Lothe.
Nat Rev Clin Oncol, 2019 Jul 11; 17(1). PMID: 31289352    Free PMC article.
Clonal tracing reveals diverse patterns of response to immune checkpoint blockade.
Shengqing Stan Gu, Xiaoqing Wang, +23 authors, X Shirley Liu.
Genome Biol, 2020 Oct 17; 21(1). PMID: 33059736    Free PMC article.
Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy.
Simone Anfossi, George A Calin.
Cancer Drug Resist, 2020 Oct 17; 3. PMID: 33062956    Free PMC article.
Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival.
Rui-Lian Chen, Jing-Xu Zhou, +8 authors, Li-Zhu Lin.
Front Immunol, 2020 Oct 20; 11. PMID: 33072067    Free PMC article.
Listeria monocytogenes cancer vaccines: bridging innate and adaptive immunity.
Zachary T Morrow, Zachary M Powers, John-Demian Sauer.
Curr Clin Microbiol Rep, 2020 Oct 20; 6(4). PMID: 33072493    Free PMC article.
Focused Ultrasound for Immunomodulation of the Tumor Microenvironment.
Jordan B Joiner, Yuliya Pylayeva-Gupta, Paul A Dayton.
J Immunol, 2020 Oct 21; 205(9). PMID: 33077668    Free PMC article.
Immunomodulatory activity of IR700-labelled affibody targeting HER2.
Justyna Mączyńska, Chiara Da Pieve, +5 authors, Gabriela Kramer-Marek.
Cell Death Dis, 2020 Oct 22; 11(10). PMID: 33082328    Free PMC article.
LncRNAs as tumor cell intrinsic factors that affect cancer immunotherapy.
Sergey D Egranov, Qingsong Hu, Chunru Lin, Liuqing Yang.
RNA Biol, 2020 May 26; 17(11). PMID: 32449433    Free PMC article.
Immunotherapy and NSCLC: The Long and Winding Road.
Antonio Rossi.
Cancers (Basel), 2020 Sep 10; 12(9). PMID: 32899647    Free PMC article.
Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology.
Ernesto Bockamp, Sebastian Rosigkeit, Dominik Siegl, Detlef Schuppan.
Cells, 2020 Sep 19; 9(9). PMID: 32942725    Free PMC article.
Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma.
Maria-Filothei Lazaridou, Chiara Massa, +7 authors, Barbara Seliger.
J Clin Med, 2020 Aug 23; 9(9). PMID: 32825219    Free PMC article.
Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching.
Maike Trommer, Jaika Kinsky, +12 authors, Christian Baues.
Cancers (Basel), 2020 Sep 02; 12(9). PMID: 32867046    Free PMC article.
Transcriptional Spatial Profiling of Cancer Tissues in the Era of Immunotherapy: The Potential and Promise.
Sanjna Nilesh Nerurkar, Denise Goh, +3 authors, Joe Poh Sheng Yeong.
Cancers (Basel), 2020 Sep 13; 12(9). PMID: 32917035    Free PMC article.
Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma.
Ilaria Grazia Zizzari, Chiara Napoletano, +12 authors, Marianna Nuti.
Cancers (Basel), 2020 Sep 18; 12(9). PMID: 32937860    Free PMC article.
Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade.
Mie Linder Hübbe, Ditte Elisabeth Jæhger, Thomas Lars Andresen, Mads Hald Andersen.
Front Immunol, 2020 Oct 27; 11. PMID: 33101304    Free PMC article.
NFE2L2 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltration in Brain Lower Grade Glioma: A Pan-Cancer Analysis.
Qiang Ju, Xinmei Li, +3 authors, Yanjie Zhao.
Oxid Med Cell Longev, 2020 Oct 27; 2020. PMID: 33101586    Free PMC article.
Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells.
Yasuyoshi Sato, Ikuo Wada, +17 authors, Kazuhiro Kakimi.
Clin Transl Immunology, 2020 Oct 27; 9(10). PMID: 33101677    Free PMC article.
DNA Repair and Signaling in Immune-Related Cancer Therapy.
Sangeeta Kakoti, Hiro Sato, +2 authors, Atsushi Shibata.
Front Mol Biosci, 2020 Oct 27; 7. PMID: 33102516    Free PMC article.
Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.
Koji Nagaoka, Masataka Shirai, +8 authors, Kazuhiro Kakimi.
J Immunother Cancer, 2020 Oct 24; 8(2). PMID: 33093158    Free PMC article.
Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon.
Beth A Helmink, Christina L Roland, Colleen M Kiernan, Jennifer A Wargo.
Ann Surg Oncol, 2020 Jan 23; 27(5). PMID: 31965370    Free PMC article.
Lung cancer treatment in the era of immunotherapy.
Yang Xu, Liang-An Chen.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969863    Free PMC article.
Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer.
Fang-Fei Qian, Bao-Hui Han.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969861    Free PMC article.
Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors.
Ragia Aly, Amandeep S Aujla, +3 authors, Sheila Kalathil.
World J Oncol, 2020 Oct 30; 11(5). PMID: 33117461    Free PMC article.
A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
Masaya Igase, Yuki Nemoto, +8 authors, Takuya Mizuno.
Sci Rep, 2020 Oct 29; 10(1). PMID: 33110170    Free PMC article.
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.
Chang Yang, Bai-Rong Xia, +3 authors, Wei-Lin Jin.
Front Immunol, 2020 Oct 31; 11. PMID: 33123161    Free PMC article.
Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer.
Charles M Haughey, Debayan Mukherjee, +14 authors, Sharon L Eddie.
Cancers (Basel), 2020 Oct 03; 12(10). PMID: 33003551    Free PMC article.
Divergent Resistance Mechanisms to Immunotherapy Explain Responses in Different Skin Cancers.
Emmanuel Dollinger, Daniel Bergman, +2 authors, Qing Nie.
Cancers (Basel), 2020 Oct 18; 12(10). PMID: 33065980    Free PMC article.
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
Leila Motedayen Aval, James E Pease, Rohini Sharma, David J Pinato.
J Clin Med, 2020 Oct 22; 9(10). PMID: 33081170    Free PMC article.
Targeting connexin 43 provides anti-inflammatory effects after intracerebral hemorrhage injury by regulating YAP signaling.
Hailong Yu, Xiang Cao, +7 authors, Yun Xu.
J Neuroinflammation, 2020 Oct 30; 17(1). PMID: 33115476    Free PMC article.
Antitumor immune response during glioma virotherapy.
Gilbert C Youssef, Candelaria Gomez-Manzano, Raymond Sawaya, Juan Fueyo.
Neuro Oncol, 2019 Jul 28; 21(9). PMID: 31348516    Free PMC article.
Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials.
Gaber Plavc, Primoz Strojan.
Radiol Oncol, 2020 Oct 17; 54(4). PMID: 33064670    Free PMC article.
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.
Vanessa Gauttier, Sabrina Pengam, +40 authors, Nicolas Poirier.
J Clin Invest, 2020 Oct 20; 130(11). PMID: 33074246    Free PMC article.
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
Yunlong Jia, Lihua Liu, Baoen Shan.
Ann Transl Med, 2020 Nov 05; 8(17). PMID: 33145314    Free PMC article.
Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications.
Johann S Bergholz, Qiwei Wang, Sheheryar Kabraji, Jean J Zhao.
Clin Cancer Res, 2020 Jun 25; 26(21). PMID: 32576627    Free PMC article.
Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
Karsten A Pilones, Michal Hensler, +5 authors, Silvia C Formenti.
Oncoimmunology, 2020 Nov 06; 9(1). PMID: 33150045    Free PMC article.
EZH2 inhibition: a promising strategy to prevent cancer immune editing.
Ning Kang, Mark Eccleston, +4 authors, Francesco Crea.
Epigenomics, 2020 Sep 18; 12(16). PMID: 32938196    Free PMC article.
β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion.
Linyong Du, Jong-Ho Lee, +15 authors, Jianxin Lyu.
J Exp Med, 2020 Aug 30; 217(11). PMID: 32860047    Free PMC article.
Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s.
Takaaki Oba, Mark D Long, +5 authors, Fumito Ito.
Nat Commun, 2020 Oct 29; 11(1). PMID: 33110069    Free PMC article.
Nature-derived compounds modulating Wnt/ -catenin pathway: a preventive and therapeutic opportunity in neoplastic diseases.
Gianluca Sferrazza, Marco Corti, +4 authors, Enrica Calleri.
Acta Pharm Sin B, 2020 Nov 10; 10(10). PMID: 33163337    Free PMC article.
Crosstalk Between Mesenchymal Stromal Cells and Tumor-Associated Macrophages in Gastric Cancer.
Ping Zheng, Wei Li.
Front Oncol, 2020 Nov 10; 10. PMID: 33163402    Free PMC article.
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
Simone Camelliti, Valentino Le Noci, +8 authors, Michele Sommariva.
J Exp Clin Cancer Res, 2020 Nov 11; 39(1). PMID: 33168050    Free PMC article.
Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies.
Kaijian Zhou, Shu Guo, +2 authors, Guoxin Liang.
Front Cell Dev Biol, 2020 Nov 13; 8. PMID: 33178688    Free PMC article.
The Influence of Tumor Microenvironment on Immune Escape of Melanoma.
Aleksandra Simiczyjew, Ewelina Dratkiewicz, +3 authors, Dorota Nowak.
Int J Mol Sci, 2020 Nov 12; 21(21). PMID: 33171792    Free PMC article.
A novel scoring method based on RNA-Seq immunograms describing individual cancer-immunity interactions.
Yukari Kobayashi, Yoshihiro Kushihara, +2 authors, Kazuhiro Kakimi.
Cancer Sci, 2020 Aug 19; 111(11). PMID: 32810311    Free PMC article.
The Resistance Mechanisms of Lung Cancer Immunotherapy.
Fen Wang, Shubin Wang, Qing Zhou.
Front Oncol, 2020 Nov 17; 10. PMID: 33194652    Free PMC article.
Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies.
Sergi Benavente, Almudena Sánchez-García, +2 authors, Juan Lorente.
Front Oncol, 2020 Nov 17; 10. PMID: 33194719    Free PMC article.
Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies.
Zhefang Wang, Fanyu Liu, +6 authors, Yue Zhao.
Front Oncol, 2020 Nov 17; 10. PMID: 33194749    Free PMC article.
Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma.
Lei Wu, Wen Quan, +3 authors, Guihai Zhang.
Front Mol Biosci, 2020 Nov 17; 7. PMID: 33195412    Free PMC article.
Tumour neoantigen heterogeneity thresholds provide a time window for combination immunotherapy.
Guim Aguadé-Gorgorió, Ricard Solé.
J R Soc Interface, 2020 Oct 29; 17(171). PMID: 33109023    Free PMC article.
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells.
Alessio Ugolini, Ilaria Grazia Zizzari, +9 authors, Marianna Nuti.
EBioMedicine, 2020 Nov 10; 62. PMID: 33166793    Free PMC article.
Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review.
Wu-Yan Xia, Wen Feng, +5 authors, Xiao-Long Fu.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209631    Free PMC article.
A sulfur dioxide polymer prodrug showing combined effect with doxorubicin in combating subcutaneous and metastatic melanoma.
Lin An, Peng Zhang, +4 authors, Chunsheng Xiao.
Bioact Mater, 2020 Nov 20; 6(5). PMID: 33210029    Free PMC article.
Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
Celia Jacoberger-Foissac, Stephen J Blake, +5 authors, Michele Wl Teng.
J Immunother Cancer, 2020 Nov 18; 8(2). PMID: 33199513    Free PMC article.
Mechanisms of resistance to CAR T cell therapies.
Nathan Singh, Elena Orlando, +5 authors, J Joseph Melenhorst.
Semin Cancer Biol, 2019 Dec 24; 65. PMID: 31866478    Free PMC article.
Tumor-infiltrating podoplanin+ cells in gastric cancer: clinical outcomes and association with immune contexture.
Xin Liu, Yifan Cao, +13 authors, Heng Zhang.
Oncoimmunology, 2020 Nov 26; 9(1). PMID: 33235820    Free PMC article.
KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression.
Xiao Albert Zhou, Jiadong Zhou, +13 authors, Jiadong Wang.
Proc Natl Acad Sci U S A, 2020 Oct 29; 117(45). PMID: 33109719    Free PMC article.
Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy.
Eun-Jin Go, Hannah Yang, +6 authors, Wooram Park.
Cancers (Basel), 2020 Oct 30; 12(11). PMID: 33114476    Free PMC article.
Breast Cancer Heterogeneity and Response to Novel Therapeutics.
Mariona Baliu-Piqué, Atanasio Pandiella, Alberto Ocana.
Cancers (Basel), 2020 Nov 11; 12(11). PMID: 33167363    Free PMC article.
Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Shuang Wu, Pilar Calero-Pérez, Carles Arús, Ana Paula Candiota.
Int J Mol Sci, 2020 Nov 26; 21(22). PMID: 33233585    Free PMC article.
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Stephen P Hack, Andrew X Zhu, Yulei Wang.
Front Immunol, 2020 Dec 01; 11. PMID: 33250900    Free PMC article.
Bioengineering of nano metal-organic frameworks for cancer immunotherapy.
Gaowei Chong, Jie Zang, +4 authors, Yongyong Li.
Nano Res, 2020 Dec 01; 14(5). PMID: 33250971    Free PMC article.
Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer.
James J Lee, Edward Chu.
Clin Colorectal Cancer, 2018 Aug 04; 17(4). PMID: 30072278    Free PMC article.
The Potential Role of Exercise and Nutrition in Harnessing the Immune System to Improve Colorectal Cancer Survival.
Mingyang Song, Andrew T Chan.
Gastroenterology, 2018 Aug 05; 155(3). PMID: 30076837    Free PMC article.
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.
Krijn K Dijkstra, Chiara M Cattaneo, +21 authors, Emile E Voest.
Cell, 2018 Aug 14; 174(6). PMID: 30100188    Free PMC article.
Highly Cited.
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.
Peng Jiang, Shengqing Gu, +12 authors, X Shirley Liu.
Nat Med, 2018 Aug 22; 24(10). PMID: 30127393    Free PMC article.
Highly Cited.
Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas.
Inês Pires da Silva, Marcel Batten, Georgina V Long.
Br J Cancer, 2018 Aug 23; 119(6). PMID: 30131552    Free PMC article.
Mechanisms of Resistance to Immune Checkpoint Blockade.
David Liu, Russell W Jenkins, Ryan J Sullivan.
Am J Clin Dermatol, 2018 Sep 28; 20(1). PMID: 30259383    Free PMC article.
Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.
Emmett V Schmidt.
Semin Immunopathol, 2018 Oct 31; 41(1). PMID: 30374524    Free PMC article.
Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy.
Alessandra Tuccitto, Eriomina Shahaj, +6 authors, Viviana Vallacchi.
Virchows Arch, 2018 Oct 31; 474(4). PMID: 30374798
Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
Elaine Tan, Bassel El-Rayes.
J Gastrointest Cancer, 2018 Nov 18; 50(1). PMID: 30446922
Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
Florian Wirsdörfer, Simone de Leve, Verena Jendrossek.
Int J Mol Sci, 2018 Dec 24; 20(1). PMID: 30577587    Free PMC article.
Alterations of the Immunologic Co-Stimulator B7 and TNFR Families Correlate with Hepatocellular Carcinoma Prognosis and Metastasis by Inactivating STAT3.
Yi-Ming Li, Zhen-Yu Liu, +5 authors, Juan Tang.
Int J Mol Sci, 2019 Jan 06; 20(1). PMID: 30609841    Free PMC article.
Cancer research in the era of immunogenomics.
Yochai Wolf, Yardena Samuels.
ESMO Open, 2019 Jan 10; 3(7). PMID: 30622743    Free PMC article.
The Adaptive Complexity of Cancer.
Youcef Derbal.
Biomed Res Int, 2019 Jan 11; 2018. PMID: 30627563    Free PMC article.
STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNFα mediated immune responses in a model of NSCLC.
Juliane Friedrich, Lisanne Heim, +4 authors, Susetta Finotto.
Oncotarget, 2019 Jan 17; 9(98). PMID: 30647851    Free PMC article.
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
Guido Giordano, Pietro Parcesepe, +13 authors, Massimo Pancione.
J Exp Clin Cancer Res, 2019 Jan 24; 38(1). PMID: 30670049    Free PMC article.
Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Christiane Margue, Demetra Philippidou, +6 authors, Stephanie Kreis.
J Exp Clin Cancer Res, 2019 Feb 08; 38(1). PMID: 30728057    Free PMC article.
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Margaret Ottaviano, Sabino De Placido, Paolo Antonio Ascierto.
Virchows Arch, 2019 Feb 13; 474(4). PMID: 30747264
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
Long Long, Chen Zhao, +3 authors, Honglei Chen.
Clin Drug Investig, 2019 Feb 20; 39(4). PMID: 30778885
3D models in the new era of immune oncology: focus on T cells, CAF and ECM.
Francesca Di Modugno, Cristina Colosi, +3 authors, Paola Nisticò.
J Exp Clin Cancer Res, 2019 Mar 23; 38(1). PMID: 30898166    Free PMC article.
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs.
Carlo Capalbo, Giorgia Scafetta, +2 authors, Armando Bartolazzi.
Int J Mol Sci, 2019 Apr 03; 20(7). PMID: 30935099    Free PMC article.
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.
Masami Iwasa, Takeshi Harada, +13 authors, Masahiro Abe.
Oncotarget, 2019 Apr 09; 10(20). PMID: 30956773    Free PMC article.
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
Giovanni Fucà, Giulia Galli, +14 authors, Diego Signorelli.
ESMO Open, 2019 Apr 10; 4(1). PMID: 30964126    Free PMC article.
Highly Cited.
Normalization cancer immunotherapy: blocking Siglec-15!
Guangchao Cao, Zhiqiang Xiao, Zhinan Yin.
Signal Transduct Target Ther, 2019 Apr 25; 4. PMID: 31016034    Free PMC article.
How many samples are needed to infer truly clonal mutations from heterogenous tumours?
Luka Opasic, Da Zhou, +2 authors, Arne Traulsen.
BMC Cancer, 2019 May 01; 19(1). PMID: 31035962    Free PMC article.
Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.
Marilina García-Aranda, Maximino Redondo.
Int J Mol Sci, 2019 May 12; 20(9). PMID: 31075880    Free PMC article.
Drug repurposing to overcome resistance to various therapies for colorectal cancer.
Winnie Fong, Kenneth K W To.
Cell Mol Life Sci, 2019 May 16; 76(17). PMID: 31087119
Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials.
Alberto Carretero-González, David Lora, +4 authors, Guillermo de Velasco.
Oncotarget, 2019 May 31; 10(35). PMID: 31143375    Free PMC article.
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series.
Matteo Lambertini, Matthias Preusser, Christoph C Zielinski.
ESMO Open, 2019 Jul 06; 4(Suppl 3). PMID: 31275617    Free PMC article.
The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment.
Stephen G Gaffney, Elizabeth B Perry, +3 authors, Jeffrey P Townsend.
Oncotarget, 2019 Jul 31; 10(44). PMID: 31360302    Free PMC article.
An elastic-net logistic regression approach to generate classifiers and gene signatures for types of immune cells and T helper cell subsets.
Arezo Torang, Paraag Gupta, David J Klinke.
BMC Bioinformatics, 2019 Aug 24; 20(1). PMID: 31438843    Free PMC article.
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Yaojie Fu, Shanshan Liu, Shan Zeng, Hong Shen.
J Exp Clin Cancer Res, 2019 Sep 11; 38(1). PMID: 31500650    Free PMC article.
Highly Cited. Review.
Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.
Daphné Morel, Daniel Jeffery, +2 authors, Sophie Postel-Vinay.
Nat Rev Clin Oncol, 2019 Oct 02; 17(2). PMID: 31570827
Highly Cited. Review.
The great escape: tumour cell plasticity in resistance to targeted therapy.
Soufiane Boumahdi, Frederic J de Sauvage.
Nat Rev Drug Discov, 2019 Oct 12; 19(1). PMID: 31601994
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
Khalil Choucair, Susan Morand, +3 authors, John Nemunaitis.
Cancer Gene Ther, 2020 Apr 29; 27(12). PMID: 32341410
Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity.
Athanasios Papadas, Garrett Arauz, +2 authors, Fotis Asimakopoulos.
J Histochem Cytochem, 2020 Jul 07; 68(12). PMID: 32623942    Free PMC article.
Targeted glycan degradation potentiates the anticancer immune response in vivo.
Melissa A Gray, Michal A Stanczak, +10 authors, Carolyn R Bertozzi.
Nat Chem Biol, 2020 Aug 19; 16(12). PMID: 32807964    Free PMC article.
Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma.
Laia Bassaganyas, Roser Pinyol, +11 authors, Josep M Llovet.
Clin Cancer Res, 2020 Sep 03; 26(23). PMID: 32873569    Free PMC article.
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
Guangchuan Wang, Ryan D Chow, +16 authors, Sidi Chen.
Cancer Discov, 2020 Sep 06; 10(12). PMID: 32887696    Free PMC article.
Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
Francesco Tovoli, Stefania De Lorenzo, Franco Trevisani.
Vaccines (Basel), 2020 Oct 08; 8(4). PMID: 33023131    Free PMC article.
Therapeutic Vaccines and Cancer Immunotherapy.
Darshak Bhatt, Toos Daemen.
Vaccines (Basel), 2020 Oct 15; 8(4). PMID: 33050488    Free PMC article.
Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review.
Qigu Yao, Lihu Gu, +2 authors, Hongcui Cao.
J Cell Mol Med, 2020 Oct 21; 24(22). PMID: 33078904    Free PMC article.
Systematic Review.
Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer.
Marra Jai Aghajani, Tao Yang, +5 authors, Tara L Roberts.
Endocr Connect, 2020 Oct 29; 9(10). PMID: 33112841    Free PMC article.
A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping.
Baptiste Louveau, Fanélie Jouenne, +14 authors, Samia Mourah.
Target Oncol, 2020 Nov 06; 15(6). PMID: 33151472
Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4.
Lisa A Marshall, Sachie Marubayashi, +16 authors, Oezcan Talay.
J Immunother Cancer, 2020 Nov 28; 8(2). PMID: 33243932    Free PMC article.
PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes.
Bridget L Menasche, Eric M Davis, +4 authors, Jingshi Shen.
Sci Adv, 2020 Nov 29; 6(48). PMID: 33246952    Free PMC article.
Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function.
Yun Wang, Kelvin Zhang, +10 authors, Sheila Ranganath.
PLoS One, 2020 Dec 04; 15(12). PMID: 33270695    Free PMC article.
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Robert Ballotti, Yann Cheli, Corine Bertolotto.
Mol Cancer, 2020 Dec 06; 19(1). PMID: 33276788    Free PMC article.
RNA sequencing: new technologies and applications in cancer research.
Mingye Hong, Shuang Tao, +6 authors, Hua Zhang.
J Hematol Oncol, 2020 Dec 06; 13(1). PMID: 33276803    Free PMC article.
Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets.
Yangying Zhou, T Mamie Lih, +11 authors, Qing Kay Li.
J Hematol Oncol, 2020 Dec 09; 13(1). PMID: 33287876    Free PMC article.
TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts.
Angelo L Grauel, Beverly Nguyen, +35 authors, Viviana Cremasco.
Nat Commun, 2020 Dec 11; 11(1). PMID: 33298926    Free PMC article.
Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy.
Xing Huang, Tianyu Tang, +5 authors, Tingbo Liang.
NPJ Precis Oncol, 2020 Dec 11; 4(1). PMID: 33299118    Free PMC article.
Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy.
Yuefei Zhu, Xiangrong Yu, +2 authors, Zhiqing Pang.
Acta Pharm Sin B, 2020 Dec 12; 10(11). PMID: 33304779    Free PMC article.
MLLT6 maintains PD-L1 expression and mediates tumor immune resistance.
Sandeep Sreevalsan, Marietta Döring, +6 authors, Mirko Theis.
EMBO Rep, 2020 Oct 17; 21(12). PMID: 33063451    Free PMC article.
Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
Yang Liu, Jing Cai, +10 authors, Jiankai Liang.
Cell Death Dis, 2020 Dec 15; 11(12). PMID: 33311488    Free PMC article.
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.
Lisa M Butler, Ylenia Perone, +6 authors, Johannes V Swinnen.
Adv Drug Deliv Rev, 2020 Jul 28; 159. PMID: 32711004    Free PMC article.
Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.
Ying Wang, Xin Zhang, +4 authors, Chengxue Dang.
Cancer Biol Ther, 2020 Nov 22; 21(12). PMID: 33218268    Free PMC article.
Multifaceted WNT Signaling at the Crossroads Between Epithelial-Mesenchymal Transition and Autophagy in Glioblastoma.
Bárbara Paranhos Coelho, Camila Felix de Lima Fernandes, +8 authors, Marilene Hohmuth Lopes.
Front Oncol, 2020 Dec 15; 10. PMID: 33312955    Free PMC article.
Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
Adham S Bear, Robert H Vonderheide, Mark H O'Hara.
Cancer Cell, 2020 Sep 19; 38(6). PMID: 32946773    Free PMC article.
Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Na Zhang, Li Wei, +2 authors, Hua You.
Front Immunol, 2020 Dec 18; 11. PMID: 33329578    Free PMC article.
Applications of Single-Cell Omics to Dissect Tumor Microenvironment.
Tingting Guo, Weimin Li, Xuyu Cai.
Front Genet, 2020 Dec 18; 11. PMID: 33329692    Free PMC article.
Regulation and Function of the PD-L1 Checkpoint.
Chong Sun, Riccardo Mezzadra, Ton N Schumacher.
Immunity, 2018 Mar 22; 48(3). PMID: 29562194    Free PMC article.
Highly Cited. Review.
Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice.
Bernd Heinrich, Zachary J Brown, +14 authors, Tim F Greten.
Gastroenterology, 2020 Oct 04; 160(1). PMID: 33010248    Free PMC article.
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
Laura Boyero, Amparo Sánchez-Gastaldo, +3 authors, Reyes Bernabé-Caro.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33322522    Free PMC article.
Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma.
Takahiro Tashiro, Kosuke Imamura, +10 authors, Takuro Sakagami.
Int J Mol Sci, 2020 Dec 24; 21(24). PMID: 33352665    Free PMC article.
Nanobodies as Versatile Tool for Multiscale Imaging Modalities.
Marco Erreni, Tilo Schorn, Francesca D'Autilia, Andrea Doni.
Biomolecules, 2020 Dec 24; 10(12). PMID: 33353213    Free PMC article.
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues.
Shin Hye Yoo, Jihui Yun, +11 authors, Dae Seog Heo.
Cancer Immunol Immunother, 2021 Jan 04; 70(6). PMID: 33389015
Evolutionary dynamics of neoantigens in growing tumors.
Eszter Lakatos, Marc J Williams, +10 authors, Trevor A Graham.
Nat Genet, 2020 Sep 16; 52(10). PMID: 32929288    Free PMC article.
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.
Yuanzhang Fang, Lifei Wang, +18 authors, Xinna Zhang.
J Clin Invest, 2020 Sep 30; 131(1). PMID: 32990678    Free PMC article.
Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells.
Md Nabiul Hasan, Lanxin Luo, +10 authors, Dandan Sun.
Theranostics, 2021 Jan 05; 11(3). PMID: 33391535    Free PMC article.
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
Jiali Yu, Michael D Green, +37 authors, Weiping Zou.
Nat Med, 2021 Jan 06; 27(1). PMID: 33398162    Free PMC article.
The immunology of renal cell carcinoma.
C Marcela Díaz-Montero, Brian I Rini, James H Finke.
Nat Rev Nephrol, 2020 Aug 01; 16(12). PMID: 32733094
Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
Johann von Felden, Amanda J Craig, +13 authors, Augusto Villanueva.
Oncogene, 2020 Oct 25; 40(1). PMID: 33097857
Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
Takao Kamai, Toshiki Kijima, +4 authors, Ken-Ichiro Yoshida.
Cancer Immunol Immunother, 2021 Jan 09; 70(7). PMID: 33416945    Free PMC article.
Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.
V Chung, F J Kos, +8 authors, D J Diamond.
Clin Transl Oncol, 2018 Aug 11; 21(3). PMID: 30094792    Free PMC article.
LNK suppresses interferon signaling in melanoma.
Ling-Wen Ding, Qiao-Yang Sun, +17 authors, H Phillip Koeffler.
Nat Commun, 2019 May 22; 10(1). PMID: 31110180    Free PMC article.
Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy.
Xuan Wang, Weiran Xu, +11 authors, Jun Guo.
Transl Oncol, 2020 Nov 23; 14(1). PMID: 33221685    Free PMC article.
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.
Michelle von Locquenghien, Catalina Rozalén, Toni Celià-Terrassa.
J Clin Invest, 2021 Jan 05; 131(1). PMID: 33393507    Free PMC article.
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.
Anastasia Mpakali, Efstratios Stratikos.
Cancers (Basel), 2021 Jan 08; 13(1). PMID: 33406696    Free PMC article.
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.
Rajasekharan Somasundaram, Thomas Connelly, +54 authors, Meenhard Herlyn.
Nat Commun, 2021 Jan 14; 12(1). PMID: 33436641    Free PMC article.
Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
Xingxing Hao, Louis D Falo Iii, +5 authors, Zhaoyang You.
J Immunother Cancer, 2021 Jan 08; 9(1). PMID: 33408093    Free PMC article.
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.
Dan You, Stephen Hillerman, +27 authors, Jinqi Liu.
J Immunother Cancer, 2021 Jan 08; 9(1). PMID: 33408094    Free PMC article.
Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis.
Qingyuan Huang, Yuzhen Zheng, +3 authors, Haiquan Chen.
J Cancer, 2021 Jan 15; 12(4). PMID: 33442411    Free PMC article.
Evolution of Lung Cancer in the Context of Immunotherapy.
Sheng Yu, Ruilin Wang, +10 authors, Yufeng Wu.
Clin Med Insights Oncol, 2021 Jan 16; 14. PMID: 33447125    Free PMC article.
Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation.
Karam Khaddour, Joshua Dowling, +6 authors, George Ansstas.
Oncotarget, 2021 Jan 16; 11(52). PMID: 33447351    Free PMC article.
Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
Zhaohan Wei, Xiaoqiong Zhang, +13 authors, Xiangliang Yang.
Nat Commun, 2021 Jan 21; 12(1). PMID: 33469052    Free PMC article.
Design for immuno-oncology clinical trials enrolling both responders and nonresponders.
Zhenzhen Xu, Bin Zhu, Yongsoek Park.
Stat Med, 2020 Sep 19; 39(27). PMID: 32944979    Free PMC article.
Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses.
Jesse M Jaynes, Rushikesh Sable, +40 authors, Udo Rudloff.
Sci Transl Med, 2020 Feb 14; 12(530). PMID: 32051227    Free PMC article.
Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors.
Salman M Toor, Varun Sasidharan Nair, +2 authors, Eyad Elkord.
Vaccines (Basel), 2021 Jan 23; 9(1). PMID: 33477864    Free PMC article.
Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
Ramin Salehi-Rad, Rui Li, +12 authors, Steven M Dubinett.
Cancer Immunol Immunother, 2021 Jan 29; 70(8). PMID: 33507343    Free PMC article.
RNF115 promotes lung adenocarcinoma through Wnt/β-catenin pathway activation by mediating APC ubiquitination.
Xiao-Ting Wu, Yu-Han Wang, +6 authors, Ming Zhang.
Cancer Metab, 2021 Jan 30; 9(1). PMID: 33509267    Free PMC article.
A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy.
Laetitia Douguet, Serena Janho Dit Hreich, +17 authors, Valérie Vouret-Craviari.
Nat Commun, 2021 Jan 30; 12(1). PMID: 33510147    Free PMC article.
Enzymatically Formed Peptide Assemblies Sequestrate Proteins and Relocate Inhibitors to Selectively Kill Cancer Cells.
Hongjian He, Shuang Liu, Difei Wu, Bing Xu.
Angew Chem Int Ed Engl, 2020 Jun 11; 59(38). PMID: 32521103    Free PMC article.
Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity.
Xiaofei Yu, Wenjie Liu, +12 authors, Xiang-Yang Wang.
J Immunother Cancer, 2021 Jan 21; 9(1). PMID: 33468554    Free PMC article.
Cancer Environment Immunotherapy: targeting TGF-β finds its way towards tissue healing and vasculature remodeling.
Ke Jin, Fangfang Zhou, Long Zhang.
Signal Transduct Target Ther, 2021 Jan 31; 6(1). PMID: 33514687    Free PMC article.
Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.
Xiaoting Wang, Kit Wong, Wenjun Ouyang, Sascha Rutz.
Cold Spring Harb Perspect Biol, 2017 Oct 19; 11(2). PMID: 29038121    Free PMC article.
PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15.
Kyung Hwan Kim, Hong Kwan Kim, +12 authors, Eui-Cheol Shin.
Cell Mol Immunol, 2020 Apr 26; 18(2). PMID: 32332901    Free PMC article.
The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Fei Zhou, Meng Qiao, Caicun Zhou.
Cell Mol Immunol, 2020 Nov 13; 18(2). PMID: 33177696    Free PMC article.
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma.
Jan Budczies, Martina Kirchner, +16 authors, Albrecht Stenzinger.
Oncoimmunology, 2021 Feb 02; 10(1). PMID: 33520406    Free PMC article.
Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.
Maria Aurora Grimaudo.
Adv Exp Med Biol, 2021 Feb 06; 1295. PMID: 33543465
Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells.
Gabriela Andrejeva, Benjamin J Capoccia, +4 authors, Daniel S Pereira.
J Immunol, 2021 Jan 13; 206(4). PMID: 33431660    Free PMC article.
[Clinical Application and Challenges of Telomere and Telomerase Research 
in Lung Cancer].
Sen Han, Xu Ma, Jian Fang.
Zhongguo Fei Ai Za Zhi, 2021 Jan 23; 24(1). PMID: 33478187    Free PMC article.
[Research Progress on the Mechanism and Clinical Data of Cereblon 
in Reversing the Resistance of Lung Cancer to PD-1 Antibody by T cells].
Jingjing Guo, Di Mu, Ying Han.
Zhongguo Fei Ai Za Zhi, 2021 Jan 23; 24(1). PMID: 33478191    Free PMC article.
The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches.
Anna Koumarianou, Jose Duran-Moreno.
Cancers (Basel), 2021 Jan 28; 13(3). PMID: 33498238    Free PMC article.
Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients.
Paul Johannet, Amelia Sawyers, +7 authors, Iman Osman.
J Transl Med, 2021 Feb 01; 19(1). PMID: 33516263    Free PMC article.
Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers.
Paola Trono, Antonella Sistigu, +2 authors, Paola Nisticò.
Emerg Top Life Sci, 2017 Dec 12; 1(5). PMID: 33525801    Free PMC article.
EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
Zhen Zhang, Hao-Xiang Wu, +4 authors, Hui-Yan Luo.
BMC Med, 2021 Feb 03; 19(1). PMID: 33526018    Free PMC article.
Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable.
Kellsye P Fabian, Anthony S Malamas, +6 authors, James W Hodge.
Cancer Immunol Res, 2020 Dec 24; 9(2). PMID: 33355290    Free PMC article.
Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment.
Valeria Lucarini, Ombretta Melaiu, +3 authors, Doriana Fruci.
Cancers (Basel), 2021 Jan 28; 13(3). PMID: 33498755    Free PMC article.
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies.
Thao N D Pham, Mario A Shields, +6 authors, Hidayatullah G Munshi.
Cancers (Basel), 2021 Jan 29; 13(3). PMID: 33503832    Free PMC article.
Tailoring precision immunotherapy: coming to a clinic soon?
Shuting Han, Wai Ho Shuen, +2 authors, Han Chong Toh.
ESMO Open, 2021 Feb 10; 5 Suppl 1. PMID: 33558033    Free PMC article.
Combinations using checkpoint blockade to overcome resistance.
Stefania Morganti, Giuseppe Curigliano.
Ecancermedicalscience, 2021 Feb 13; 14. PMID: 33574893    Free PMC article.
A gene expression-based immune signature for lung adenocarcinoma prognosis.
Lijuan Wang, Xizhi Luo, +3 authors, Feifei Xiao.
Cancer Immunol Immunother, 2020 May 07; 69(9). PMID: 32372138
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Yihe Yan, Leting Zheng, +2 authors, David A Geller.
Cancer Immunol Immunother, 2020 May 08; 69(9). PMID: 32377817